<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceutics</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceutics</journal-id><journal-id journal-id-type="publisher-id">pharmaceutics</journal-id><journal-title-group><journal-title>Pharmaceutics</journal-title></journal-title-group><issn pub-type="epub">1999-4923</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40006584</article-id><article-id pub-id-type="pmc">PMC11859475</article-id><article-id pub-id-type="doi">10.3390/pharmaceutics17020217</article-id><article-id pub-id-type="publisher-id">pharmaceutics-17-00217</article-id><article-categories><subj-group subj-group-type="heading"><subject>Systematic Review</subject></subj-group></article-categories><title-group><article-title>Riboflavin-Mediated Photodynamic Therapy in Periodontology: A Systematic Review of Applications and Outcomes</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0009-3173-9389</contrib-id><name><surname>Fiegler-Rudol</surname><given-names>Jakub</given-names></name><xref rid="c1-pharmaceutics-17-00217" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>&#x00141;opaci&#x00144;ski</surname><given-names>Maciej</given-names></name></contrib><contrib contrib-type="author"><name><surname>Los</surname><given-names>Artur</given-names></name></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-8732-251X</contrib-id><name><surname>Skaba</surname><given-names>Dariusz</given-names></name></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5673-7413</contrib-id><name><surname>Wiench</surname><given-names>Rafa&#x00142;</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Bakowsky</surname><given-names>Udo</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Gon&#x000e7;alves</surname><given-names>Renato Sonchini</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Braga</surname><given-names>Gustavo</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pharmaceutics-17-00217">Department of Periodontal Diseases and Oral Mucosa Diseases, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 40-055 Katowice, Poland; <email>mlopacinski@sum.edu.pl</email> (M.&#x00141;.); <email>s79893@365.sum.edu.pl</email> (A.L.); <email>dskaba@sum.edu.pl</email> (D.S.); <email>rwiench@sum.edu.pl</email> (R.W.)</aff><author-notes><corresp id="c1-pharmaceutics-17-00217"><label>*</label>Correspondence: <email>jakub.fiegler@gmail.com</email></corresp></author-notes><pub-date pub-type="epub"><day>07</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>17</volume><issue>2</issue><elocation-id>217</elocation-id><history><date date-type="received"><day>19</day><month>1</month><year>2025</year></date><date date-type="rev-recd"><day>31</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>05</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p><bold>Background</bold>: Riboflavin (vitamin B<sub>2</sub>) has emerged as a promising photosensitizer in photodynamic therapy (PDT) due to its strong absorption of blue light and favourable safety profile. This systematic review aims to evaluate the efficacy of riboflavin-mediated PDT in periodontology, specifically examining its antimicrobial effects and potential to improve clinical outcomes compared to conventional or other PDT-based treatments. <bold>Methods</bold>: A systematic review was conducted following PRISMA guidelines. A comprehensive literature search was performed in PubMed/Medline, Embase, Scopus, and the Cochrane Library. Studies published in English within the last 10 years were considered, where riboflavin served as the primary photosensitizer for dental treatments. Data extraction focused on study design, photosensitizer concentration, light source parameters, and clinical or microbiological outcomes. The risk of bias was assessed independently by two reviewers using a predefined scoring system. <bold>Results</bold>: Ten studies met the inclusion criteria, all demonstrating a low risk of bias. Riboflavin-mediated PDT consistently reduced microbial biofilms and pathogen viability in periodontitis, peri-implantitis, and endodontic models. Although some studies reported slightly lower efficacy compared to chlorhexidine or toluidine blue&#x02013;based PDT, riboflavin-mediated PDT exhibited advantages such as minimal staining, low cytotoxicity, and enhanced collagen crosslinking. However, most studies were in vitro or small-scale clinical trials, limiting conclusions on long-term effectiveness. <bold>Conclusions</bold>: Riboflavin-mediated PDT shows promise as a safe adjunctive therapy for periodontal infections. Larger, well-designed clinical trials with standardized parameters and extended follow-up are needed to further evaluate its efficacy and optimize treatment protocols for routine clinical application.</p></abstract><kwd-group><kwd>riboflavin</kwd><kwd>photodynamic therapy</kwd><kwd>periodontics</kwd><kwd>periodontal infections</kwd><kwd>biofilms</kwd><kwd>antimicrobial therapy</kwd><kwd>blue light activation</kwd><kwd>dental treatments</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmaceutics-17-00217"><title>1. Introduction</title><sec id="sec1dot1-pharmaceutics-17-00217"><title>1.1. Rationale</title><p>Riboflavin, commonly known as vitamin B<sub>2</sub>, is an essential water-soluble vitamin involved in numerous biochemical processes such as cellular metabolism, redox reactions, and the maintenance of tissue integrity [<xref rid="B1-pharmaceutics-17-00217" ref-type="bibr">1</xref>,<xref rid="B2-pharmaceutics-17-00217" ref-type="bibr">2</xref>,<xref rid="B3-pharmaceutics-17-00217" ref-type="bibr">3</xref>]. In addition to its well-known nutritional benefits, riboflavin has gained prominence as a powerful photosensitizing agent in photodynamic therapy (PDT), a minimally invasive treatment modality that is increasingly used in various medical fields, including dentistry [<xref rid="B4-pharmaceutics-17-00217" ref-type="bibr">4</xref>,<xref rid="B5-pharmaceutics-17-00217" ref-type="bibr">5</xref>]. Photodynamic therapy integrates three core components: a photosensitizer, light of a specific wavelength, and molecular oxygen [<xref rid="B6-pharmaceutics-17-00217" ref-type="bibr">6</xref>]. When these elements interact, they generate reactive oxygen species (ROS) that effectively mediate antimicrobial activity, induce cellular damage in pathogens, and modify target tissue structures [<xref rid="B4-pharmaceutics-17-00217" ref-type="bibr">4</xref>,<xref rid="B7-pharmaceutics-17-00217" ref-type="bibr">7</xref>]. The duration of action for riboflavin-mediated photodynamic therapy (PDT) depends on the specific treatment protocol, including factors such as the irradiation time, riboflavin concentration, light source used, and the clinical condition being treated [<xref rid="B4-pharmaceutics-17-00217" ref-type="bibr">4</xref>,<xref rid="B7-pharmaceutics-17-00217" ref-type="bibr">7</xref>,<xref rid="B8-pharmaceutics-17-00217" ref-type="bibr">8</xref>,<xref rid="B9-pharmaceutics-17-00217" ref-type="bibr">9</xref>]. A schematic representation of this is presented in <xref rid="pharmaceutics-17-00217-f001" ref-type="fig">Figure 1</xref>.</p><p>Riboflavin is ideally suited for PDT because it effectively absorbs blue light and exhibits excellent biocompatibility [<xref rid="B8-pharmaceutics-17-00217" ref-type="bibr">8</xref>,<xref rid="B9-pharmaceutics-17-00217" ref-type="bibr">9</xref>]. It shows absorption peaks around 225, 275, 380, and 450 nm. Although these wavelengths do not penetrate deeply into tissues, this limitation may not pose a major issue when bacterial contamination is largely superficial. Additionally, the limited tissue penetration of blue light (405&#x02013;470 nm) can serve as a benefit by safeguarding patient tissues from extensive photodamage [<xref rid="B10-pharmaceutics-17-00217" ref-type="bibr">10</xref>]. The gold standard treatment for periodontitis currently involves the combination of systemic and local antibiotic therapies with root planing, effectively targeting pathogenic bacteria and promoting the restoration of periodontal health [<xref rid="B7-pharmaceutics-17-00217" ref-type="bibr">7</xref>,<xref rid="B10-pharmaceutics-17-00217" ref-type="bibr">10</xref>,<xref rid="B11-pharmaceutics-17-00217" ref-type="bibr">11</xref>].</p><p>The mechanism of riboflavin-mediated PDT is multifaceted. Upon exposure to light at an appropriate wavelength, riboflavin transitions from its ground state to an excited singlet state, enabling it to interact with molecular oxygen in its environment [<xref rid="B11-pharmaceutics-17-00217" ref-type="bibr">11</xref>]. This interaction produces ROS, such as singlet oxygen and free radicals, that inflict oxidative damage on bacterial membranes, proteins, and DNA, thereby effectively inactivating pathogens [<xref rid="B11-pharmaceutics-17-00217" ref-type="bibr">11</xref>,<xref rid="B12-pharmaceutics-17-00217" ref-type="bibr">12</xref>]. Beyond its antimicrobial effects, photoactivated riboflavin also enhances collagen cross-linking within dentin. This process strengthens the organic matrix and improves the long-term stability of adhesive bonds, making riboflavin-mediated PDT a versatile tool for both microbial control and structural reinforcement in dental procedures [<xref rid="B13-pharmaceutics-17-00217" ref-type="bibr">13</xref>].</p><p>Riboflavin-mediated PDT offers several advantages over traditional dental treatments. Conventional disinfectants such as sodium hypochlorite and chlorhexidine, while effective, carry risks of cytotoxicity and tissue irritation [<xref rid="B14-pharmaceutics-17-00217" ref-type="bibr">14</xref>,<xref rid="B15-pharmaceutics-17-00217" ref-type="bibr">15</xref>]. Likewise, techniques like phosphoric acid etching can be invasive and potentially weaken enamel or dentin [<xref rid="B16-pharmaceutics-17-00217" ref-type="bibr">16</xref>]. In contrast, riboflavin-mediated PDT is minimally invasive, non-toxic, and preserves tissue integrity while delivering robust antimicrobial activity [<xref rid="B17-pharmaceutics-17-00217" ref-type="bibr">17</xref>]. Moreover, its capacity to stabilize the dentin matrix through collagen cross-linking helps inhibit enzymatic degradation by matrix metalloproteinases (MMPs), which is crucial for maintaining the durability of adhesive bonds [<xref rid="B18-pharmaceutics-17-00217" ref-type="bibr">18</xref>]. These beneficial properties position riboflavin-mediated PDT as an attractive alternative or adjunct to existing protocols, especially for applications such as disinfecting caries-affected dentin, reconditioning enamel, and enhancing bond strength in adhesive dentistry [<xref rid="B15-pharmaceutics-17-00217" ref-type="bibr">15</xref>,<xref rid="B16-pharmaceutics-17-00217" ref-type="bibr">16</xref>,<xref rid="B17-pharmaceutics-17-00217" ref-type="bibr">17</xref>,<xref rid="B18-pharmaceutics-17-00217" ref-type="bibr">18</xref>,<xref rid="B19-pharmaceutics-17-00217" ref-type="bibr">19</xref>].</p></sec><sec id="sec1dot2-pharmaceutics-17-00217"><title>1.2. Objectives</title><p>The primary objective of this systematic review is to assess the current evidence regarding the efficacy of riboflavin-mediated PDT in the treatment of various dental conditions. This includes evaluating its antimicrobial effects, its ability to reduce biofilm mass, and its potential to improve clinical outcomes when used alone or in combination with other treatments. Additionally, this review aims to identify the optimal parameters for riboflavin-mediated PDT, including light source specifications and photosensitizer concentrations, to provide evidence-based recommendations for its clinical application. By consolidating findings from in vitro, clinical, and animal studies, this review seeks to highlight the strengths and limitations of riboflavin-mediated PDT, inform future research directions, and potentially facilitate its integration into routine clinical practice.</p></sec></sec><sec id="sec2-pharmaceutics-17-00217"><title>2. Materials and Methods</title><sec id="sec2dot1-pharmaceutics-17-00217"><title>2.1. Focused Question and Null Hypothesis</title><p>A systematic review was undertaken using the PICO framework and structured as follows [<xref rid="B20-pharmaceutics-17-00217" ref-type="bibr">20</xref>]: For patients diagnosed with dental infections or conditions such as peri-implantitis, periodontitis, endodontic infections, or orthodontic biofilms (Population), does the implementation of riboflavin-mediated photodynamic therapy (Intervention), in comparison to conventional treatments such as mechanical debridement, curcumin-mediated PDT, or other non-surgical therapies (Comparison), lead to more effective management, reduced microbial load, or improved clinical outcomes (Outcome)? The null hypothesis for this study posits that there is no significant difference in the effectiveness of managing dental infections or improving clinical outcomes when using riboflavin-mediated photodynamic therapy compared to conventional mechanical debridement, curcumin-mediated PDT, or other non-surgical treatments.</p></sec><sec id="sec2dot2-pharmaceutics-17-00217"><title>2.2. Search Strategy</title><p>This systematic review was registered with PROSPERO CRD42025635828 and adhered to the PRISMA 2020 guidelines to ensure clarity and transparency in reporting [<xref rid="B21-pharmaceutics-17-00217" ref-type="bibr">21</xref>]. A comprehensive search strategy was implemented across several databases, including PubMed/Medline, Embase, Scopus, and the Cochrane Library, using predefined keywords, which are listed in <xref rid="pharmaceutics-17-00217-t001" ref-type="table">Table 1</xref>. Three researchers conducted the database searches independently, employing consistent methodologies. The review included studies published in English between 1 January 2015, and 3 January 2025, based on predefined inclusion criteria. Two authors (J.F-R. and R.W.) screened studies at the title, abstract, and full-text levels. Additionally, reference lists of eligible studies were examined to identify further relevant publications. The findings suggest that photodynamic therapy using riboflavin and curcumin may serve as a promising alternative or complementary approach to conventional peri-implantitis treatments, supported by a careful selection of high-quality studies.</p></sec><sec id="sec2dot3-pharmaceutics-17-00217"><title>2.3. Selection of Studies</title><p>In the selection phase of this systematic review, each reviewer independently assessed the titles and abstracts of the retrieved studies to ensure objective inclusion. If disagreements about a study&#x02019;s eligibility arose, the reviewers collaborated and discussed the matter until a consensus was achieved. This rigorous process, adhering to PRISMA guidelines, ensured that only the most pertinent and methodologically sound studies were included, thereby improving the reliability and reproducibility of the review [<xref rid="B21-pharmaceutics-17-00217" ref-type="bibr">21</xref>].</p><p>The inclusion criteria for this systematic review focused on studies that utilized riboflavin-based PDT for various dental conditions, including both in vitro and animal research. Additionally, research that explored the combined effects of riboflavin-mediated PDT with other antimicrobial or anti-inflammatory treatments was considered. Studies with control groups comparing riboflavin-based PDT to standard mechanical debridement, alternative non-surgical therapies, or no treatment were included, as well as investigations that directly compared the effectiveness of riboflavin-mediated PDT with other non-surgical treatments. Long-term studies assessing the sustained impact of riboflavin-mediated PDT on dental health outcomes, such as infection control, inflammation reduction, and tissue healing, were also included. Only publications that met predefined quality standards (<xref rid="pharmaceutics-17-00217-t002" ref-type="table">Table 2</xref>) and specifically addressed the improvement or management of dental conditions using riboflavin-mediated PDT were considered.</p><p>Exclusion criteria included grey and unpublished literature, such as dissertations, conference abstracts, theses, and non-peer-reviewed materials, as well as articles published in languages other than English. Duplicate publications or those with identical ethical approval numbers were excluded. Studies focusing on dental or medical issues outside the scope of this review were also excluded, along with those using alternative photosensitizers other than riboflavin in PDT. Non-relevant in vitro studies that did not replicate clinical dental conditions or address pertinent microbial strains were not included. Furthermore, non-primary data formats such as case reports, case series, narrative reviews, systematic reviews, editorials, and books were excluded, as were studies lacking a control or comparison group. Lastly, studies involving non-therapeutic uses of PDT were not considered.</p></sec><sec id="sec2dot4-pharmaceutics-17-00217"><title>2.4. Risk of Bias in Individual Studies and Quality Assessment</title><p>At the start of the study selection process for this systematic review, each reviewer individually examined the titles and abstracts of the identified articles on riboflavin-mediated photodynamic therapy in dental treatments to reduce the risk of bias. The agreement between reviewers was measured using Cohen&#x02019;s kappa statistic, ensuring consistent and reliable decision-making [<xref rid="B22-pharmaceutics-17-00217" ref-type="bibr">22</xref>]. In cases where disagreements about a study&#x02019;s eligibility occurred, the reviewers discussed the issues thoroughly until they reached a unanimous agreement.</p><p>The methodological quality of the included studies was independently assessed by two reviewers and focused on critical aspects of riboflavin-mediated photodynamic therapy (PDT) protocols, including study design, execution, and data analysis to maintain objectivity and reliable outcomes. Potential biases were identified by assigning a score of 1 for each &#x0201c;yes&#x0201d; and 0 for each &#x0201c;no&#x0201d; response, based on the following evaluation criteria: (1) Was a specific concentration of riboflavin clearly defined and utilized as the photosensitizer? (2) Was the origin or source of the riboflavin disclosed in the study? (3) Was the incubation period for the riboflavin photosensitizer explicitly stated? (4) Were detailed specifications of the light source provided, including type, wavelength, output power, fluence, and power density? (5) Was a power meter employed to accurately measure the light parameters used in the study? (6) Was a negative control group included in the experimental design to provide a baseline for comparison? (7) Were numerical results presented, accompanied by appropriate statistical analyses? (8) Was there complete reporting of outcome data without any missing information? (9) Funding Independence: Was the study conducted independently of its funding sources to prevent potential conflicts of interest? (10) Were participants and/or investigators blinded to the treatment allocations to minimize bias? Each study&#x02019;s risk of bias was then classified based on the total number of &#x0201c;yes&#x0201d; responses: High Risk of Bias (0&#x02013;3 points), Moderate Risk of Bias (4&#x02013;6 points), and Low Risk of Bias (7&#x02013;10 points). The total score was calculated for each study, and the corresponding bias risk level (low, moderate, or high) was determined according to the guidelines outlined in the Cochrane Handbook for Systematic Reviews of Interventions [<xref rid="B23-pharmaceutics-17-00217" ref-type="bibr">23</xref>]. This rigorous quality assessment process ensured that only studies with robust and reliable methodologies were included in the systematic review, thereby enhancing the overall validity and credibility of the review&#x02019;s findings.</p><p><xref rid="pharmaceutics-17-00217-t002" ref-type="table">Table 2</xref> provides a detailed evaluation of the risk of bias for the 10 studies included in the final analysis. Inclusion criteria required each study to score at least six points according to the established evaluation framework. All selected studies demonstrated a low risk of bias, with one study achieving the highest possible score of 10 points [<xref rid="B24-pharmaceutics-17-00217" ref-type="bibr">24</xref>]. Importantly, no studies were classified as having a moderate or high risk of bias, reinforcing the reliability and robustness of the systematic review&#x02019;s findings.</p><table-wrap position="anchor" id="pharmaceutics-17-00217-t002"><object-id pub-id-type="pii">pharmaceutics-17-00217-t002_Table 2</object-id><label>Table 2</label><caption><p>The results of the quality assessment and risk of bias across the studies.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Author(s)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">1</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">2</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">3</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">4</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">5</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">6</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">7</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">8</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">9</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">10</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Total</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Risk</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Afrasiabi et al., 2023 [<xref rid="B25-pharmaceutics-17-00217" ref-type="bibr">25</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">8</td><td align="center" valign="middle" rowspan="1" colspan="1">Low</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">B&#x000e4;renfaller et al., 2016 [<xref rid="B26-pharmaceutics-17-00217" ref-type="bibr">26</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">Low</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Comeau et al., 2022 [<xref rid="B27-pharmaceutics-17-00217" ref-type="bibr">27</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">Low</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Etemadi et al., 2023 [<xref rid="B28-pharmaceutics-17-00217" ref-type="bibr">28</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">Low</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Kang et al., 2019 [<xref rid="B29-pharmaceutics-17-00217" ref-type="bibr">29</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">Low</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Kunz et al., 2019 [<xref rid="B30-pharmaceutics-17-00217" ref-type="bibr">30</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">8</td><td align="center" valign="middle" rowspan="1" colspan="1">Low</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Leelanarathiwata et al., 2020 [<xref rid="B31-pharmaceutics-17-00217" ref-type="bibr">31</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">8</td><td align="center" valign="middle" rowspan="1" colspan="1">Low</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Morelato et al., 2022 [<xref rid="B32-pharmaceutics-17-00217" ref-type="bibr">32</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">Low</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Nielsen et al., 2015 [<xref rid="B33-pharmaceutics-17-00217" ref-type="bibr">33</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">8</td><td align="center" valign="middle" rowspan="1" colspan="1">Low</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Qamar et al., 2023 [<xref rid="B24-pharmaceutics-17-00217" ref-type="bibr">24</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Low</td></tr></tbody></table></table-wrap></sec><sec id="sec2dot5-pharmaceutics-17-00217"><title>2.5. Data Extraction</title><p>After finalizing the selection of pertinent studies, the two reviewers extracted detailed information from each included article. This extraction process encompassed bibliographic details such as the lead author&#x02019;s name and the year of publication, the study design, the specific dental conditions addressed, and the types of experimental and control groups utilized. Additionally, they documented the length of follow-up periods, the outcomes measured related to dental treatment effectiveness, and the technical specifications of the light sources used, including type, wavelength, and power parameters. Furthermore, the reviewers meticulously recorded the concentrations of riboflavin employed as the photosensitizer, the use of nanocarriers or other supplementary agents, as well as the incubation and irradiation durations during photodynamic therapy. They also captured information on any adjunctive treatments or methodologies integrated into the studies. This comprehensive data extraction ensured that all relevant variables were thoroughly captured, enabling a robust and exhaustive analysis of the efficacy and operational parameters of riboflavin-mediated photodynamic therapy in various dental treatments. This systematic approach to data extraction facilitated a nuanced understanding of how riboflavin-mediated PDT performs across different clinical scenarios, thereby strengthening the overall reliability and depth of the systematic review.</p></sec></sec><sec sec-type="results" id="sec3-pharmaceutics-17-00217"><title>3. Results</title><sec id="sec3dot1-pharmaceutics-17-00217"><title>3.1. Study Selection</title><p><xref rid="pharmaceutics-17-00217-f002" ref-type="fig">Figure 2</xref> presents an overview of the research workflow, meticulously designed to follow the PRISMA guidelines [<xref rid="B23-pharmaceutics-17-00217" ref-type="bibr">23</xref>]. The process began with an initial literature search that identified 37 articles. After eliminating duplicates, 30 records remained. A thorough screening of titles and abstracts was conducted, resulting in 10 studies being chosen for a full-text review. Notably, no studies were excluded during this phase. In the end, 10 studies published within the last decade were included in the final analysis. <xref rid="pharmaceutics-17-00217-t003" ref-type="table">Table 3</xref> provides a detailed summary of these selected studies.</p></sec><sec id="sec3dot2-pharmaceutics-17-00217"><title>3.2. Data Presentation</title><p>Data from the 10 studies meeting the inclusion criteria were carefully extracted and are systematically summarized in <xref rid="pharmaceutics-17-00217-t003" ref-type="table">Table 3</xref>, <xref rid="pharmaceutics-17-00217-t004" ref-type="table">Table 4</xref>, <xref rid="pharmaceutics-17-00217-t005" ref-type="table">Table 5</xref> and <xref rid="pharmaceutics-17-00217-t006" ref-type="table">Table 6</xref>. These tables provide an extensive overview of each study&#x02019;s key features, including the characteristics of the light sources used and the specific properties of riboflavin employed as a photosensitiser in PDT protocols. This structured presentation enables detailed comparisons and comprehensive analysis of riboflavin-based PDT across the selected studies, supporting a robust assessment of its effectiveness and methodological aspects in addressing dental conditions.</p></sec><sec id="sec3dot3-pharmaceutics-17-00217"><title>3.3. General Characteristics of the Included Studies</title><p>The general characteristics of the 10 included studies are shown in <xref rid="pharmaceutics-17-00217-t003" ref-type="table">Table 3</xref>, <xref rid="pharmaceutics-17-00217-t004" ref-type="table">Table 4</xref>, <xref rid="pharmaceutics-17-00217-t005" ref-type="table">Table 5</xref> and <xref rid="pharmaceutics-17-00217-t006" ref-type="table">Table 6</xref>.</p></sec><sec id="sec3dot4-pharmaceutics-17-00217"><title>3.4. Main Study Outcomes</title><p>The reviewed studies underscore the significant potential of riboflavin-mediated PDT for managing microbial biofilms and infections in various periodontal and dental applications. Riboflavin, a biocompatible photosensitizer, generates ROS such as singlet oxygen and hydrogen peroxide when activated by UV or blue light, effectively disrupting microbial cells and biofilms [<xref rid="B25-pharmaceutics-17-00217" ref-type="bibr">25</xref>,<xref rid="B26-pharmaceutics-17-00217" ref-type="bibr">26</xref>]. In orthodontic treatments, riboflavin-mediated PDT notably reduced microbial populations around brackets, thereby addressing challenges posed by conventional biofilm management strategies [<xref rid="B25-pharmaceutics-17-00217" ref-type="bibr">25</xref>]. On implant surfaces, riboflavin-mediated PDT significantly decreased <italic toggle="yes">Aggregatibacter actinomycetemcomitans</italic> biofilms, though its efficacy was slightly lower than chlorhexidine or curcumin-mediated PDT [<xref rid="B28-pharmaceutics-17-00217" ref-type="bibr">28</xref>,<xref rid="B29-pharmaceutics-17-00217" ref-type="bibr">29</xref>]. In addition, studies have demonstrated its dose-dependent ability to reduce <italic toggle="yes">Enterococcus faecalis</italic> biofilm formation, with higher riboflavin concentrations and optimized laser parameters improving disinfection outcomes [<xref rid="B25-pharmaceutics-17-00217" ref-type="bibr">25</xref>]. While results suggest that riboflavin-mediated PDT may be less potent than sodium hypochlorite in some cases, it has the advantage of causing minimal discolouration, indicating its potential as a safer alternative for root canal disinfection [<xref rid="B25-pharmaceutics-17-00217" ref-type="bibr">25</xref>]. Furthermore, riboflavin-loaded dental resins exhibit enhanced mechanical stability and antimicrobial properties, offering avenues for further optimization [<xref rid="B27-pharmaceutics-17-00217" ref-type="bibr">27</xref>]. Similar findings on titanium implants indicate that riboflavin-mediated PDT, activated with a 445 nm diode laser, achieves comparable biofilm reductions to methylene blue&#x02013;based PDT and chlorhexidine, with the added benefit of minimal staining&#x02014;an important consideration for aesthetic zones [<xref rid="B32-pharmaceutics-17-00217" ref-type="bibr">32</xref>]. Overall, these results support riboflavin-PDT as a promising adjunctive therapy in periodontology, providing safety, biocompatibility, and material preservation. However, additional research is required to refine its antimicrobial efficacy and determine its value as a standalone clinical treatment.</p></sec></sec><sec sec-type="discussion" id="sec4-pharmaceutics-17-00217"><title>4. Discussion</title><sec id="sec4dot1-pharmaceutics-17-00217"><title>4.1. Results in the Context of Other Evidence</title><p>Riboflavin-mediated PDT, activated by blue diode lasers or LEDs, has shown significant antimicrobial effects, particularly at higher light power densities [<xref rid="B25-pharmaceutics-17-00217" ref-type="bibr">25</xref>]. Although it effectively reduces single-species bacterial counts, its efficacy decreases in complex multi-species biofilms&#x02014;especially when serum is present&#x02014;underscoring the importance of adjunctive mechanical biofilm removal [<xref rid="B26-pharmaceutics-17-00217" ref-type="bibr">26</xref>]. In comparison to the gold standard treatment for periodontitis, which typically involves systemic and local antibiotic administration alongside root planing, riboflavin-mediated PDT offers a targeted antimicrobial strategy that is minimally invasive and may reduce the risk of antibiotic resistance [<xref rid="B26-pharmaceutics-17-00217" ref-type="bibr">26</xref>,<xref rid="B27-pharmaceutics-17-00217" ref-type="bibr">27</xref>,<xref rid="B28-pharmaceutics-17-00217" ref-type="bibr">28</xref>]. Riboflavin-loaded resin systems may facilitate integration into restorative dentistry by providing both antimicrobial activity and mechanical stability [<xref rid="B27-pharmaceutics-17-00217" ref-type="bibr">27</xref>]. However, their limited penetration into deeper biofilms suggests that additional strategies are required to enhance treatment efficacy in more complex microbial environments. They offer limited penetration into deeper biofilms, which could indicate a need for a photosensitizer that can be excited at a longer wavelength [<xref rid="B28-pharmaceutics-17-00217" ref-type="bibr">28</xref>]. Riboflavin-mediated PDT also exhibits selective antimicrobial action, effectively reducing certain pathogens such as <italic toggle="yes">Veillonella parvula</italic> but not others, including <italic toggle="yes">Lactobacillus gasseri</italic> [<xref rid="B29-pharmaceutics-17-00217" ref-type="bibr">29</xref>]. Pre-treatment with hydrogen peroxide significantly boosts its effectiveness, particularly when coupled with mechanical debridement [<xref rid="B30-pharmaceutics-17-00217" ref-type="bibr">30</xref>]. This combination was particularly effective in reducing complex multi-species biofilms, which are typically more resistant to single-agent treatments. In peri-implantitis, riboflavin-based PDT achieves bacterial reductions comparable to methylene blue&#x02013;based PDT with red lasers, thus offering a promising option in aesthetically sensitive areas [<xref rid="B31-pharmaceutics-17-00217" ref-type="bibr">31</xref>,<xref rid="B32-pharmaceutics-17-00217" ref-type="bibr">32</xref>]. Nonetheless, alternative photosensitizers like toluidine blue O (TBO) under red light may provide more comprehensive microbial eradication in certain clinical scenarios [<xref rid="B33-pharmaceutics-17-00217" ref-type="bibr">33</xref>]. More recent strategies, such as combining riboflavin-loaded nanoparticles in aloe vera gel with mechanical debridement, further improve clinical outcomes by reducing probing depth and microbial load more effectively than PDT alone [<xref rid="B24-pharmaceutics-17-00217" ref-type="bibr">24</xref>]. These combinatory approaches highlight the potential for enhanced therapeutic protocols that integrate riboflavin-mediated PDT with other adjunctive treatments to overcome existing limitations. While riboflavin-mediated PDT presents a non-invasive alternative with a lower risk of antibiotic resistance, additional research is necessary to refine treatment protocols, enhance effectiveness in complex biofilms, and assess long-term clinical applications [<xref rid="B24-pharmaceutics-17-00217" ref-type="bibr">24</xref>,<xref rid="B25-pharmaceutics-17-00217" ref-type="bibr">25</xref>,<xref rid="B26-pharmaceutics-17-00217" ref-type="bibr">26</xref>,<xref rid="B27-pharmaceutics-17-00217" ref-type="bibr">27</xref>,<xref rid="B28-pharmaceutics-17-00217" ref-type="bibr">28</xref>,<xref rid="B29-pharmaceutics-17-00217" ref-type="bibr">29</xref>,<xref rid="B30-pharmaceutics-17-00217" ref-type="bibr">30</xref>,<xref rid="B31-pharmaceutics-17-00217" ref-type="bibr">31</xref>,<xref rid="B32-pharmaceutics-17-00217" ref-type="bibr">32</xref>,<xref rid="B33-pharmaceutics-17-00217" ref-type="bibr">33</xref>,<xref rid="B34-pharmaceutics-17-00217" ref-type="bibr">34</xref>].</p><p>Several recent studies underscore the broad potential of riboflavin-mediated PDT across various dental and medical applications. &#x00141;opaci&#x00144;ski et al. [<xref rid="B14-pharmaceutics-17-00217" ref-type="bibr">14</xref>] demonstrated its effectiveness against oral candidiasis, whereas Etemadi et al. [<xref rid="B35-pharmaceutics-17-00217" ref-type="bibr">35</xref>] found that riboflavin, when photoactivated by blue light, could substantially reduce periodontitis-related bacteria. Notably, Etemadi et al. also reported that blue light alone produced significant bacterial reductions in some cases, highlighting the need for further investigations to delineate riboflavin&#x02019;s specific contribution as a photosensitizer. In the orthodontic context, Alqerban et al. [<xref rid="B36-pharmaceutics-17-00217" ref-type="bibr">36</xref>] reported that applying 0.1% riboflavin in PDT effectively bonded orthodontic brackets and conferred considerable antibacterial benefits. Increasing the riboflavin concentration to 0.5% enhanced antimicrobial efficacy yet compromised bonding strength, indicating a trade-off. Kamran et al. [<xref rid="B37-pharmaceutics-17-00217" ref-type="bibr">37</xref>] similarly confirmed that riboflavin-mediated PDT markedly reduced <italic toggle="yes">Streptococcus mutans</italic> and <italic toggle="yes">Streptococcus sanguinis</italic> levels around orthodontic brackets, underscoring its promise for improving antimicrobial control in orthodontic treatments. Moradi et al. [<xref rid="B38-pharmaceutics-17-00217" ref-type="bibr">38</xref>] showed that antimicrobial PDT using curcumin or riboflavin significantly reduced <italic toggle="yes">Enterococcus faecalis</italic> biofilms in root canals, achieving comparable results to 5.25% NaOCl. While NaOCl produced the highest bacterial reduction, these findings support PDT as a viable adjunct for root canal disinfection. Beyond oral applications, Najari et al. [<xref rid="B39-pharmaceutics-17-00217" ref-type="bibr">39</xref>] suggested that riboflavin-mediated PDT, when combined with antibiotics such as colistin, could be valuable for difficult-to-treat <italic toggle="yes">Pseudomonas aeruginosa</italic> infections. Additionally, Alshehri et al. [<xref rid="B40-pharmaceutics-17-00217" ref-type="bibr">40</xref>] showed that riboflavin-mediated PDT offered the highest antifungal efficacy against <italic toggle="yes">Candida albicans</italic> on acrylic denture surfaces without damaging the denture material. Arboleda et al. [<xref rid="B41-pharmaceutics-17-00217" ref-type="bibr">41</xref>], however, found that rose bengal&#x02013;mediated PDT, rather than riboflavin-mediated PDT, effectively inhibited the growth of three fungal species in a corneal infection model. Finally, Kashiwabuchi et al. emphasized that continued refinement in riboflavin preparation and light delivery could further enhance the therapeutic outcomes of riboflavin-mediated PDT, reinforcing the need for additional in vitro and clinical trial [<xref rid="B42-pharmaceutics-17-00217" ref-type="bibr">42</xref>]. While in situ gels like Atridox provide sustained doxycycline release without the need for additional equipment, riboflavin-mediated PDT requires photoactivation but offers selective antimicrobial action and potential integration into restorative dental materials, and further research is needed to fully evaluate and optimize both approaches for managing complex periodontal infections [<xref rid="B43-pharmaceutics-17-00217" ref-type="bibr">43</xref>,<xref rid="B44-pharmaceutics-17-00217" ref-type="bibr">44</xref>,<xref rid="B45-pharmaceutics-17-00217" ref-type="bibr">45</xref>,<xref rid="B46-pharmaceutics-17-00217" ref-type="bibr">46</xref>,<xref rid="B47-pharmaceutics-17-00217" ref-type="bibr">47</xref>]. The integration of riboflavin-mediated PDT into various clinical practices demonstrates significant potential, yet highlights the necessity for ongoing optimization and validation through further research [<xref rid="B23-pharmaceutics-17-00217" ref-type="bibr">23</xref>,<xref rid="B24-pharmaceutics-17-00217" ref-type="bibr">24</xref>,<xref rid="B25-pharmaceutics-17-00217" ref-type="bibr">25</xref>,<xref rid="B26-pharmaceutics-17-00217" ref-type="bibr">26</xref>,<xref rid="B27-pharmaceutics-17-00217" ref-type="bibr">27</xref>,<xref rid="B28-pharmaceutics-17-00217" ref-type="bibr">28</xref>,<xref rid="B29-pharmaceutics-17-00217" ref-type="bibr">29</xref>,<xref rid="B30-pharmaceutics-17-00217" ref-type="bibr">30</xref>,<xref rid="B31-pharmaceutics-17-00217" ref-type="bibr">31</xref>,<xref rid="B32-pharmaceutics-17-00217" ref-type="bibr">32</xref>,<xref rid="B33-pharmaceutics-17-00217" ref-type="bibr">33</xref>,<xref rid="B34-pharmaceutics-17-00217" ref-type="bibr">34</xref>,<xref rid="B35-pharmaceutics-17-00217" ref-type="bibr">35</xref>,<xref rid="B36-pharmaceutics-17-00217" ref-type="bibr">36</xref>,<xref rid="B37-pharmaceutics-17-00217" ref-type="bibr">37</xref>,<xref rid="B38-pharmaceutics-17-00217" ref-type="bibr">38</xref>,<xref rid="B39-pharmaceutics-17-00217" ref-type="bibr">39</xref>,<xref rid="B40-pharmaceutics-17-00217" ref-type="bibr">40</xref>,<xref rid="B41-pharmaceutics-17-00217" ref-type="bibr">41</xref>,<xref rid="B42-pharmaceutics-17-00217" ref-type="bibr">42</xref>,<xref rid="B43-pharmaceutics-17-00217" ref-type="bibr">43</xref>,<xref rid="B44-pharmaceutics-17-00217" ref-type="bibr">44</xref>].</p></sec><sec id="sec4dot2-pharmaceutics-17-00217"><title>4.2. Limitations of the Evidence</title><p>Despite the promising outcomes reported, several limitations in the current body of evidence constrain a definitive assessment of riboflavin-mediated PDT in periodontology. First, the marked heterogeneity in study protocols, ranging from the type and intensity of light sources to the concentration of riboflavin and the duration of exposure, makes direct comparisons challenging and precludes the establishment of standardized guidelines [<xref rid="B21-pharmaceutics-17-00217" ref-type="bibr">21</xref>,<xref rid="B24-pharmaceutics-17-00217" ref-type="bibr">24</xref>,<xref rid="B25-pharmaceutics-17-00217" ref-type="bibr">25</xref>,<xref rid="B26-pharmaceutics-17-00217" ref-type="bibr">26</xref>,<xref rid="B27-pharmaceutics-17-00217" ref-type="bibr">27</xref>,<xref rid="B28-pharmaceutics-17-00217" ref-type="bibr">28</xref>,<xref rid="B29-pharmaceutics-17-00217" ref-type="bibr">29</xref>,<xref rid="B30-pharmaceutics-17-00217" ref-type="bibr">30</xref>,<xref rid="B31-pharmaceutics-17-00217" ref-type="bibr">31</xref>,<xref rid="B32-pharmaceutics-17-00217" ref-type="bibr">32</xref>,<xref rid="B33-pharmaceutics-17-00217" ref-type="bibr">33</xref>]. Additionally, most of the included studies were in vitro, limiting the generalizability of their findings to clinical practice [<xref rid="B24-pharmaceutics-17-00217" ref-type="bibr">24</xref>,<xref rid="B25-pharmaceutics-17-00217" ref-type="bibr">25</xref>,<xref rid="B26-pharmaceutics-17-00217" ref-type="bibr">26</xref>,<xref rid="B27-pharmaceutics-17-00217" ref-type="bibr">27</xref>,<xref rid="B28-pharmaceutics-17-00217" ref-type="bibr">28</xref>,<xref rid="B29-pharmaceutics-17-00217" ref-type="bibr">29</xref>,<xref rid="B30-pharmaceutics-17-00217" ref-type="bibr">30</xref>,<xref rid="B31-pharmaceutics-17-00217" ref-type="bibr">31</xref>,<xref rid="B32-pharmaceutics-17-00217" ref-type="bibr">32</xref>,<xref rid="B33-pharmaceutics-17-00217" ref-type="bibr">33</xref>]. Even among the few in vivo or clinical trials, sample sizes were frequently small and follow-up times relatively short, raising questions about long-term efficacy and safety [<xref rid="B24-pharmaceutics-17-00217" ref-type="bibr">24</xref>,<xref rid="B25-pharmaceutics-17-00217" ref-type="bibr">25</xref>,<xref rid="B26-pharmaceutics-17-00217" ref-type="bibr">26</xref>,<xref rid="B27-pharmaceutics-17-00217" ref-type="bibr">27</xref>,<xref rid="B28-pharmaceutics-17-00217" ref-type="bibr">28</xref>,<xref rid="B29-pharmaceutics-17-00217" ref-type="bibr">29</xref>,<xref rid="B30-pharmaceutics-17-00217" ref-type="bibr">30</xref>,<xref rid="B31-pharmaceutics-17-00217" ref-type="bibr">31</xref>,<xref rid="B32-pharmaceutics-17-00217" ref-type="bibr">32</xref>,<xref rid="B33-pharmaceutics-17-00217" ref-type="bibr">33</xref>]. Moreover, outcome measures often relied on colony-forming units or visually assessed biofilm reduction without consistent use of advanced or standardized diagnostic tools [<xref rid="B24-pharmaceutics-17-00217" ref-type="bibr">24</xref>,<xref rid="B25-pharmaceutics-17-00217" ref-type="bibr">25</xref>,<xref rid="B26-pharmaceutics-17-00217" ref-type="bibr">26</xref>,<xref rid="B27-pharmaceutics-17-00217" ref-type="bibr">27</xref>,<xref rid="B28-pharmaceutics-17-00217" ref-type="bibr">28</xref>,<xref rid="B29-pharmaceutics-17-00217" ref-type="bibr">29</xref>,<xref rid="B30-pharmaceutics-17-00217" ref-type="bibr">30</xref>,<xref rid="B31-pharmaceutics-17-00217" ref-type="bibr">31</xref>,<xref rid="B32-pharmaceutics-17-00217" ref-type="bibr">32</xref>,<xref rid="B33-pharmaceutics-17-00217" ref-type="bibr">33</xref>]. Two major issues are the scattering of short-wavelength light, which limits efficacy, and the possibility that photokilling a portion of the cell population could lead to the development of an unresponsive group of cells, which were not addressed by the studies analysed [<xref rid="B29-pharmaceutics-17-00217" ref-type="bibr">29</xref>,<xref rid="B33-pharmaceutics-17-00217" ref-type="bibr">33</xref>]. Finally, potential biases, such as the lack of blinding and reliance on subjective endpoints, further highlight the need for more robust, controlled clinical trials with uniform protocols, larger cohorts, and longer observation periods [<xref rid="B21-pharmaceutics-17-00217" ref-type="bibr">21</xref>,<xref rid="B22-pharmaceutics-17-00217" ref-type="bibr">22</xref>,<xref rid="B23-pharmaceutics-17-00217" ref-type="bibr">23</xref>].</p></sec><sec id="sec4dot3-pharmaceutics-17-00217"><title>4.3. Limitations of the Review Process</title><p>A key limitation of the review process relates to the marked heterogeneity of study designs, intervention protocols, and outcome measures, which necessitated a largely narrative synthesis rather than a quantitative meta-analysis. While PRISMA guidelines were followed to enhance transparency, the exclusion of non-English studies and grey literature potentially narrowed the scope, increasing the risk of missing relevant data. Furthermore, although study selection and data extraction were conducted in duplicate, the reliance on authors&#x02019; subjective judgments may introduce inadvertent bias. Finally, the decision not to apply the GRADE framework, due to substantial variability in parameters and methodologies, limits the ability to draw definitive conclusions about the overall certainty of the evidence. These factors highlight the need for more uniform protocols and comprehensive strategies in future systematic reviews of riboflavin-mediated photodynamic therapy in periodontology.</p></sec><sec id="sec4dot4-pharmaceutics-17-00217"><title>4.4. Implications for Practice, Policy, and Future Research</title><p>Riboflavin-mediated PDT shows considerable promise as an adjunctive or alternative strategy in periodontal care, especially for managing biofilm-related infections and potentially reducing reliance on conventional antimicrobials. Clinically, practitioners could integrate riboflavin-mediated PDT into existing protocols for periodontal debridement or implant maintenance, leveraging its generally low toxicity and minimal staining profile compared to other photosensitizers. From a policy perspective, regulatory bodies and professional organizations should consider supporting standardized protocols and guidelines to facilitate consistent implementation across different clinical settings. This includes establishing optimal light parameters, riboflavin concentrations, and treatment durations to maximize therapeutic efficacy. In parallel, future research must focus on high-quality randomized controlled trials with robust sample sizes and longer follow-up to validate riboflavin-mediated PDT&#x02019;s effectiveness in vivo. Investigations into combination therapies, such as pairing PDT with other antimicrobial or anti-inflammatory agents and innovations in photosensitizer delivery methods (e.g., nanoparticles or bioactive materials) may further enhance treatment outcomes. Through these combined efforts, riboflavin-mediated PDT stands to gain broader acceptance and become an integral component of evidence-based periodontal care.</p></sec></sec><sec sec-type="conclusions" id="sec5-pharmaceutics-17-00217"><title>5. Conclusions</title><p>The findings of this systematic review suggest that riboflavin-mediated PDT holds considerable promise for enhancing antimicrobial efficacy and clinical outcomes in periodontology. Although the heterogeneity in study designs and outcome measures precludes a definitive consensus, the cumulative evidence indicates that riboflavin-mediated PDT often compares favourably, or at least equivalently, to conventional interventions such as mechanical debridement. Consequently, while the results do not uniformly or unequivocally refute the null hypothesis, which posits no significant difference in effectiveness between riboflavin-mediated PDT and established non-surgical therapies, they do increasingly challenge it. Notably, riboflavin-mediated PDT demonstrated advantages in reducing biofilm mass, minimizing staining, and potentially lowering the risk of antibiotic resistance. To provide more conclusive guidance for clinical practice, future well-designed randomized controlled trials with standardized protocols, larger cohorts, and extended follow-up periods are needed to fully determine whether riboflavin-mediated PDT indeed offers a superior or distinct therapeutic benefit in periodontal care.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, M.&#x00141;. and R.W.; methodology, J.F-R. and R.W.; software, M.&#x00141;. and J.F.-R.; formal analysis, J.F.-R., A.L. and M.&#x00141;.; investigation, J.F.-R. and M.&#x00141;.; writing&#x02014;original draft preparation, J.F-R., A.L., R.W. and M.&#x00141;.; writing&#x02014;review and editing, A.L., J.F.-R., M.&#x00141;., R.W. and D.S.; supervision, R.W. and D.S.; funding acquisition, R.W. and D.S. All authors have read and agreed to the published version of the manuscript.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-pharmaceutics-17-00217"><label>1.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Peechakara</surname><given-names>B.V.</given-names></name>
<name><surname>Sina</surname><given-names>R.E.</given-names></name>
<name><surname>Gupta</surname><given-names>M.</given-names></name>
</person-group><article-title>Vitamin B2 (Riboflavin) [Updated 1 February 2024]</article-title><source>StatPearls [Internet]</source><publisher-name>StatPearls Publishing</publisher-name><publisher-loc>Treasure Island, FL, USA</publisher-loc><year>2025</year><comment>Available online: <ext-link xlink:href="https://ncbi.nlm.nih.gov/books/NBK525977/" ext-link-type="uri">https://ncbi.nlm.nih.gov/books/NBK525977/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-02-04">(accessed on 4 February 2025)</date-in-citation></element-citation></ref><ref id="B2-pharmaceutics-17-00217"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Averianova</surname><given-names>L.A.</given-names></name>
<name><surname>Balabanova</surname><given-names>L.A.</given-names></name>
<name><surname>Son</surname><given-names>O.M.</given-names></name>
<name><surname>Podvolotskaya</surname><given-names>A.B.</given-names></name>
<name><surname>Tekutyeva</surname><given-names>L.A.</given-names></name>
</person-group><article-title>Production of Vitamin B2 (Riboflavin) by Microorganisms: An Overview</article-title><source>Front. Bioeng. Biotechnol.</source><year>2020</year><volume>8</volume><elocation-id>570828</elocation-id><pub-id pub-id-type="doi">10.3389/fbioe.2020.570828</pub-id><pub-id pub-id-type="pmid">33304888</pub-id>
</element-citation></ref><ref id="B3-pharmaceutics-17-00217"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Powers</surname><given-names>H.J.</given-names></name>
</person-group><article-title>Riboflavin (vitamin B2) health</article-title><source>Am. J. Clin. Nutr.</source><year>2003</year><volume>77</volume><fpage>1352</fpage><lpage>1360</lpage><pub-id pub-id-type="doi">10.1093/ajcn/77.6.1352</pub-id><pub-id pub-id-type="pmid">12791609</pub-id>
</element-citation></ref><ref id="B4-pharmaceutics-17-00217"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Insi&#x00144;ska-Rak</surname><given-names>M.</given-names></name>
<name><surname>Sikorski</surname><given-names>M.</given-names></name>
<name><surname>Wolnicka-Glubisz</surname><given-names>A.</given-names></name>
</person-group><article-title>Riboflavin and Its Derivates as Potential Photosensitizers in the Photodynamic Treatment of Skin Cancers</article-title><source>Cells</source><year>2023</year><volume>12</volume><elocation-id>2304</elocation-id><!--<pub-id pub-id-type="pmcid">PMC10528563</pub-id>--><pub-id pub-id-type="doi">10.3390/cells12182304</pub-id><pub-id pub-id-type="pmid">37759526</pub-id>
</element-citation></ref><ref id="B5-pharmaceutics-17-00217"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Niculescu</surname><given-names>A.G.</given-names></name>
<name><surname>Grumezescu</surname><given-names>A.M.</given-names></name>
</person-group><article-title>Photodynamic Therapy&#x02014;An Up-to-Date Review</article-title><source>Appl. Sci.</source><year>2021</year><volume>11</volume><elocation-id>3626</elocation-id><pub-id pub-id-type="doi">10.3390/app11083626</pub-id></element-citation></ref><ref id="B6-pharmaceutics-17-00217"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Correia</surname><given-names>J.H.</given-names></name>
<name><surname>Rodrigues</surname><given-names>J.A.</given-names></name>
<name><surname>Pimenta</surname><given-names>S.</given-names></name>
<name><surname>Dong</surname><given-names>T.</given-names></name>
<name><surname>Yang</surname><given-names>Z.</given-names></name>
</person-group><article-title>Photodynamic Therapy Review: Principles, Photosensitizers, Applications, and Future Directions</article-title><source>Pharmaceutics</source><year>2021</year><volume>13</volume><elocation-id>1332</elocation-id><!--<pub-id pub-id-type="pmcid">PMC8470722</pub-id>--><pub-id pub-id-type="doi">10.3390/pharmaceutics13091332</pub-id><pub-id pub-id-type="pmid">34575408</pub-id>
</element-citation></ref><ref id="B7-pharmaceutics-17-00217"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alfei</surname><given-names>S.</given-names></name>
<name><surname>Schito</surname><given-names>G.C.</given-names></name>
<name><surname>Schito</surname><given-names>A.M.</given-names></name>
<name><surname>Zuccari</surname><given-names>G.</given-names></name>
</person-group><article-title>Reactive Oxygen Species (ROS)-Mediated Antibacterial Oxidative Therapies: Available Methods to Generate ROS and a Novel Option Proposal</article-title><source>Int. J. Mol. Sci.</source><year>2024</year><volume>25</volume><elocation-id>7182</elocation-id><!--<pub-id pub-id-type="pmcid">PMC11241369</pub-id>--><pub-id pub-id-type="doi">10.3390/ijms25137182</pub-id><pub-id pub-id-type="pmid">39000290</pub-id>
</element-citation></ref><ref id="B8-pharmaceutics-17-00217"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Azizi</surname><given-names>A.</given-names></name>
<name><surname>Shohrati</surname><given-names>P.</given-names></name>
<name><surname>Goudarzi</surname><given-names>M.</given-names></name>
<name><surname>Lawaf</surname><given-names>S.</given-names></name>
<name><surname>Rahimi</surname><given-names>A.</given-names></name>
</person-group><article-title>Comparison of the effect of photodynamic therapy with curcumin and methylene Blue on streptococcus mutans bacterial colonies</article-title><source>Photodiagnosis Photodyn. Ther.</source><year>2019</year><volume>27</volume><fpage>203</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1016/j.pdpdt.2019.06.002</pub-id><pub-id pub-id-type="pmid">31176042</pub-id>
</element-citation></ref><ref id="B9-pharmaceutics-17-00217"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pordel</surname><given-names>E.</given-names></name>
<name><surname>Ghasemi</surname><given-names>T.</given-names></name>
<name><surname>Afrasiabi</surname><given-names>S.</given-names></name>
<name><surname>Benedicenti</surname><given-names>S.</given-names></name>
<name><surname>Signore</surname><given-names>A.</given-names></name>
<name><surname>Chiniforush</surname><given-names>N.</given-names></name>
</person-group><article-title>The Effect of Different Output Powers of Blue Diode Laser along with Curcumin and Riboflavin against <italic toggle="yes">Streptococcus mutans</italic> around Orthodontic Brackets: An In Vitro Study</article-title><source>Biomedicines</source><year>2023</year><volume>11</volume><elocation-id>2248</elocation-id><!--<pub-id pub-id-type="pmcid">PMC10452080</pub-id>--><pub-id pub-id-type="doi">10.3390/biomedicines11082248</pub-id><pub-id pub-id-type="pmid">37626744</pub-id>
</element-citation></ref><ref id="B10-pharmaceutics-17-00217"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schlafer</surname><given-names>S.</given-names></name>
<name><surname>Vaeth</surname><given-names>M.</given-names></name>
<name><surname>H&#x000f8;rsted-Bindslev</surname><given-names>P.</given-names></name>
<name><surname>Frandsen</surname><given-names>E.V.</given-names></name>
</person-group><article-title>Endodontic photoactivated disinfection using a conventional light source: An in vitro and ex vivo study</article-title><source>Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endodontology</source><year>2010</year><volume>109</volume><fpage>634</fpage><lpage>641</lpage><pub-id pub-id-type="doi">10.1016/j.tripleo.2009.12.027</pub-id><pub-id pub-id-type="pmid">20303060</pub-id>
</element-citation></ref><ref id="B11-pharmaceutics-17-00217"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Abrahamse</surname><given-names>H.</given-names></name>
<name><surname>Hamblin</surname><given-names>M.R.</given-names></name>
</person-group><article-title>New photosensitizers for photodynamic therapy</article-title><source>Biochem. J.</source><year>2016</year><volume>473</volume><fpage>347</fpage><lpage>364</lpage><!--<pub-id pub-id-type="pmcid">PMC4811612</pub-id>--><pub-id pub-id-type="doi">10.1042/BJ20150942</pub-id><pub-id pub-id-type="pmid">26862179</pub-id>
</element-citation></ref><ref id="B12-pharmaceutics-17-00217"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kashef</surname><given-names>N.</given-names></name>
<name><surname>Hamblin</surname><given-names>M.R.</given-names></name>
</person-group><article-title>Can microbial cells develop resistance to oxidative stress in antimicrobial photodynamic inactivation?</article-title><source>Drug Resist. Updat.</source><year>2017</year><volume>31</volume><fpage>31</fpage><lpage>42</lpage><!--<pub-id pub-id-type="pmcid">PMC5673603</pub-id>--><pub-id pub-id-type="doi">10.1016/j.drup.2017.07.003</pub-id><pub-id pub-id-type="pmid">28867242</pub-id>
</element-citation></ref><ref id="B13-pharmaceutics-17-00217"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>H.</given-names></name>
<name><surname>Sun</surname><given-names>G.</given-names></name>
<name><surname>Wang</surname><given-names>H.</given-names></name>
<name><surname>Yu</surname><given-names>S.</given-names></name>
<name><surname>Tian</surname><given-names>Z.</given-names></name>
<name><surname>Zhu</surname><given-names>S.</given-names></name>
</person-group><article-title>Effect of collagen cross-linkers on dentin bond strength: A systematic review and network meta-analysis</article-title><source>Front. Bioeng. Biotechnol.</source><year>2023</year><volume>10</volume><elocation-id>1100894</elocation-id><!--<pub-id pub-id-type="pmcid">PMC9903368</pub-id>--><pub-id pub-id-type="doi">10.3389/fbioe.2022.1100894</pub-id><pub-id pub-id-type="pmid">36760752</pub-id>
</element-citation></ref><ref id="B14-pharmaceutics-17-00217"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>&#x00141;opaci&#x00144;ski</surname><given-names>M.</given-names></name>
<name><surname>Fiegler-Rudol</surname><given-names>J.</given-names></name>
<name><surname>Niemczyk</surname><given-names>W.</given-names></name>
<name><surname>Skaba</surname><given-names>D.</given-names></name>
<name><surname>Wiench</surname><given-names>R.</given-names></name>
</person-group><article-title>Riboflavin- and Hypericin-Mediated Antimicrobial Photodynamic Therapy as Alternative Treatments for Oral Candidiasis: A Systematic Review</article-title><source>Pharmaceutics</source><year>2025</year><volume>17</volume><elocation-id>33</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics17010033</pub-id></element-citation></ref><ref id="B15-pharmaceutics-17-00217"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Khoury</surname><given-names>R.D.</given-names></name>
<name><surname>de Carvalho</surname><given-names>L.S.</given-names></name>
<name><surname>do Nascimento</surname><given-names>M.F.R.</given-names></name>
<name><surname>Alhussain</surname><given-names>F.</given-names></name>
<name><surname>Abu Hasna</surname><given-names>A.</given-names></name>
</person-group><article-title>Endodontic irrigants from a comprehensive perspective</article-title><source>World J. Clin. Cases</source><year>2024</year><volume>12</volume><fpage>4460</fpage><lpage>4468</lpage><!--<pub-id pub-id-type="pmcid">PMC11235474</pub-id>--><pub-id pub-id-type="doi">10.12998/wjcc.v12.i21.4460</pub-id><pub-id pub-id-type="pmid">39070803</pub-id>
</element-citation></ref><ref id="B16-pharmaceutics-17-00217"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pashley</surname><given-names>D.H.</given-names></name>
<name><surname>Tay</surname><given-names>F.R.</given-names></name>
<name><surname>Breschi</surname><given-names>L.</given-names></name>
<name><surname>Tj&#x000e4;derhane</surname><given-names>L.</given-names></name>
<name><surname>Carvalho</surname><given-names>R.M.</given-names></name>
<name><surname>Carrilho</surname><given-names>M.</given-names></name>
<name><surname>Tezvergil-Mutluay</surname><given-names>A.</given-names></name>
</person-group><article-title>State of the art etch-and-rinse adhesives</article-title><source>Dent. Mater.</source><year>2011</year><volume>27</volume><fpage>1</fpage><lpage>16</lpage><!--<pub-id pub-id-type="pmcid">PMC3857593</pub-id>--><pub-id pub-id-type="doi">10.1016/j.dental.2010.10.016</pub-id><pub-id pub-id-type="pmid">21112620</pub-id>
</element-citation></ref><ref id="B17-pharmaceutics-17-00217"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>De Silva</surname><given-names>P.</given-names></name>
<name><surname>Saad</surname><given-names>M.A.</given-names></name>
<name><surname>Thomsen</surname><given-names>H.C.</given-names></name>
<name><surname>Bano</surname><given-names>S.</given-names></name>
<name><surname>Ashraf</surname><given-names>S.</given-names></name>
<name><surname>Hasan</surname><given-names>T.</given-names></name>
</person-group><article-title>Photodynamic therapy, priming and optical imaging: Potential co-conspirators in treatment design and optimization&#x02014;A Thomas Dougherty Award for Excellence in PDT paper</article-title><source>J. Porphyr. Phthalocyanines</source><year>2020</year><volume>24</volume><fpage>1320</fpage><lpage>1360</lpage><!--<pub-id pub-id-type="pmcid">PMC10327884</pub-id>--><pub-id pub-id-type="doi">10.1142/S1088424620300098</pub-id><pub-id pub-id-type="pmid">37425217</pub-id>
</element-citation></ref><ref id="B18-pharmaceutics-17-00217"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>de Moraes</surname><given-names>I.Q.S.</given-names></name>
<name><surname>do Nascimento</surname><given-names>T.G.</given-names></name>
<name><surname>da Silva</surname><given-names>A.T.</given-names></name>
<name><surname>de Lira</surname><given-names>L.M.S.S.</given-names></name>
<name><surname>Parolia</surname><given-names>A.</given-names></name>
<name><surname>Porto</surname><given-names>I.C.C.M.</given-names></name>
</person-group><article-title>Inhibition of matrix metalloproteinases: A troubleshooting for dentin adhesion</article-title><source>Restor. Dent. Endod.</source><year>2020</year><volume>45</volume><fpage>e31</fpage><!--<pub-id pub-id-type="pmcid">PMC7431940</pub-id>--><pub-id pub-id-type="doi">10.5395/rde.2020.45.e31</pub-id><pub-id pub-id-type="pmid">32839712</pub-id>
</element-citation></ref><ref id="B19-pharmaceutics-17-00217"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alrefeai</surname><given-names>M.</given-names></name>
<name><surname>Aljamhan</surname><given-names>A.</given-names></name>
<name><surname>Al Habdan</surname><given-names>A.H.</given-names></name>
<name><surname>Alzehiri</surname><given-names>M.</given-names></name>
<name><surname>Naseem</surname><given-names>M.</given-names></name>
<name><surname>Alkhudhairy</surname><given-names>F.</given-names></name>
</person-group><article-title>Influence of methylene blue, riboflavin, and indocyanine green on the bond strength of caries-affected dentin when bonded to resin-modified glass ionomer cement</article-title><source>Photodiagnosis Photodyn. Ther.</source><year>2022</year><volume>38</volume><fpage>102792</fpage><pub-id pub-id-type="doi">10.1016/j.pdpdt.2022.102792</pub-id><pub-id pub-id-type="pmid">35257973</pub-id>
</element-citation></ref><ref id="B20-pharmaceutics-17-00217"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schardt</surname><given-names>C.</given-names></name>
<name><surname>Adams</surname><given-names>M.B.</given-names></name>
<name><surname>Owens</surname><given-names>T.</given-names></name>
<name><surname>Keitz</surname><given-names>S.</given-names></name>
<name><surname>Fontelo</surname><given-names>P.</given-names></name>
</person-group><article-title>Utilization of the PICO Framework to Improve Searching PubMed for Clinical Questions</article-title><source>BMC Med. Inform. Decis. Mak.</source><year>2007</year><volume>7</volume><elocation-id>16</elocation-id><pub-id pub-id-type="doi">10.1186/1472-6947-7-16</pub-id><pub-id pub-id-type="pmid">17573961</pub-id>
</element-citation></ref><ref id="B21-pharmaceutics-17-00217"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Page</surname><given-names>M.J.</given-names></name>
<name><surname>McKenzie</surname><given-names>J.E.</given-names></name>
<name><surname>Bossuyt</surname><given-names>P.M.</given-names></name>
<name><surname>Boutron</surname><given-names>I.</given-names></name>
<name><surname>Hoffmann</surname><given-names>T.C.</given-names></name>
<name><surname>Mulrow</surname><given-names>C.D.</given-names></name>
<name><surname>Shamseer</surname><given-names>L.</given-names></name>
<name><surname>Tetzlaff</surname><given-names>J.M.</given-names></name>
<name><surname>Akl</surname><given-names>E.A.</given-names></name>
<name><surname>Brennan</surname><given-names>S.E.</given-names></name>
<etal/>
</person-group><article-title>The PRISMA 2020 statement: An updated guideline for reporting systematic reviews</article-title><source>BMJ</source><year>2021</year><volume>372</volume><fpage>n71</fpage><pub-id pub-id-type="doi">10.1136/bmj.n71</pub-id><pub-id pub-id-type="pmid">33782057</pub-id>
</element-citation></ref><ref id="B22-pharmaceutics-17-00217"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Watson</surname><given-names>P.F.</given-names></name>
<name><surname>Petrie</surname><given-names>A.</given-names></name>
</person-group><article-title>Method Agreement Analysis: A Review of Correct Methodology</article-title><source>Theriogenology</source><year>2010</year><volume>73</volume><fpage>1167</fpage><lpage>1179</lpage><pub-id pub-id-type="doi">10.1016/j.theriogenology.2010.01.003</pub-id><pub-id pub-id-type="pmid">20138353</pub-id>
</element-citation></ref><ref id="B23-pharmaceutics-17-00217"><label>23.</label><element-citation publication-type="book"><person-group person-group-type="editor">
<name><surname>Higgins</surname><given-names>J.P.T.</given-names></name>
<name><surname>Thomas</surname><given-names>J.</given-names></name>
<name><surname>Chandler</surname><given-names>J.</given-names></name>
<name><surname>Cumpston</surname><given-names>M.</given-names></name>
<name><surname>Li</surname><given-names>T.</given-names></name>
<name><surname>Page</surname><given-names>M.J.</given-names></name>
<name><surname>Welch</surname><given-names>V.A.</given-names></name>
</person-group><source>Cochrane Handbook for Systematic Reviews of Interventions</source><edition>2nd ed.</edition><publisher-name>Wiley-Blackwell</publisher-name><publisher-loc>Chichester, UK</publisher-loc><year>2019</year><pub-id pub-id-type="doi">10.1002/9781119536604</pub-id></element-citation></ref><ref id="B24-pharmaceutics-17-00217"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Qamar</surname><given-names>Z.</given-names></name>
<name><surname>Sayed Abdul</surname><given-names>N.</given-names></name>
<name><surname>Soman</surname><given-names>C.</given-names></name>
<name><surname>Shenoy</surname><given-names>M.</given-names></name>
<name><surname>Bamousa</surname><given-names>B.</given-names></name>
<name><surname>Rabea</surname><given-names>S.</given-names></name>
<name><surname>Albahkaly</surname><given-names>H.S.</given-names></name>
</person-group><article-title>Clinical and radiographic peri-implant outcomes with riboflavin-loaded Poly-L-glycolic acid nanoparticles incorporated in aloe-vera gel treating peri-implantitis in chronic hyperglycemic patients</article-title><source>Photodiagnosis Photodyn. Ther.</source><year>2023</year><volume>44</volume><fpage>103752</fpage><pub-id pub-id-type="doi">10.1016/j.pdpdt.2023.103752</pub-id><pub-id pub-id-type="pmid">37595657</pub-id>
</element-citation></ref><ref id="B25-pharmaceutics-17-00217"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Afrasiabi</surname><given-names>S.</given-names></name>
<name><surname>Entezari</surname><given-names>S.</given-names></name>
<name><surname>Etemadi</surname><given-names>A.</given-names></name>
<name><surname>Chiniforush</surname><given-names>N.</given-names></name>
</person-group><article-title>The influence of different modes of power density during antimicrobial photodynamic therapy for photokilling of <italic toggle="yes">Streptococcus mutans</italic></article-title><source>Photodiagnosis Photodyn. Ther.</source><year>2023</year><volume>44</volume><fpage>103770</fpage><pub-id pub-id-type="doi">10.1016/j.pdpdt.2023.103770</pub-id><pub-id pub-id-type="pmid">37640204</pub-id>
</element-citation></ref><ref id="B26-pharmaceutics-17-00217"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>B&#x000e4;renfaller</surname><given-names>V.</given-names></name>
<name><surname>Clausen</surname><given-names>C.</given-names></name>
<name><surname>Sculean</surname><given-names>A.</given-names></name>
<name><surname>Eick</surname><given-names>S.</given-names></name>
</person-group><article-title>Effect of photoactivated disinfection using light in the blue spectrum</article-title><source>J. Photochem. Photobiol. B</source><year>2016</year><volume>158</volume><fpage>252</fpage><lpage>257</lpage><pub-id pub-id-type="doi">10.1016/j.jphotobiol.2016.03.006</pub-id><pub-id pub-id-type="pmid">26994334</pub-id>
</element-citation></ref><ref id="B27-pharmaceutics-17-00217"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Comeau</surname><given-names>P.</given-names></name>
<name><surname>Burgess</surname><given-names>J.</given-names></name>
<name><surname>Rezqi Qomi</surname><given-names>N.</given-names></name>
<name><surname>Lee</surname><given-names>A.</given-names></name>
<name><surname>Manso</surname><given-names>A.</given-names></name>
</person-group><article-title>The antimicrobial, physical, and chemical properties of a riboflavin-loaded dental resin intended for antimicrobial photodynamic therapy</article-title><source>Photodiagnosis Photodyn. Ther.</source><year>2022</year><volume>40</volume><fpage>103124</fpage><pub-id pub-id-type="doi">10.1016/j.pdpdt.2022.103124</pub-id><pub-id pub-id-type="pmid">36602068</pub-id>
</element-citation></ref><ref id="B28-pharmaceutics-17-00217"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Etemadi</surname><given-names>A.</given-names></name>
<name><surname>Hashemi</surname><given-names>S.S.</given-names></name>
<name><surname>Chiniforush</surname><given-names>N.</given-names></name>
</person-group><article-title>Evaluation of the effect of photodynamic therapy with curcumin and riboflavin on implant surface contaminated with <italic toggle="yes">Aggregatibacter actinomycetemcomitans</italic></article-title><source>Photodiagnosis Photodyn. Ther.</source><year>2023</year><volume>44</volume><fpage>103833</fpage><pub-id pub-id-type="doi">10.1016/j.pdpdt.2023.103833</pub-id><pub-id pub-id-type="pmid">37802275</pub-id>
</element-citation></ref><ref id="B29-pharmaceutics-17-00217"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kang</surname><given-names>S.M.</given-names></name>
<name><surname>Jung</surname><given-names>H.I.</given-names></name>
<name><surname>Kim</surname><given-names>B.I.</given-names></name>
</person-group><article-title>Susceptibility of oral bacteria to antibacterial photodynamic therapy</article-title><source>J. Oral Microbiol.</source><year>2019</year><volume>11</volume><elocation-id>1644111</elocation-id><pub-id pub-id-type="doi">10.1080/20002297.2019.1644111</pub-id><pub-id pub-id-type="pmid">31448062</pub-id>
</element-citation></ref><ref id="B30-pharmaceutics-17-00217"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kunz</surname><given-names>D.</given-names></name>
<name><surname>Wirth</surname><given-names>J.</given-names></name>
<name><surname>Sculean</surname><given-names>A.</given-names></name>
<name><surname>Eick</surname><given-names>S.</given-names></name>
</person-group><article-title>In-vitro activity of additive application of hydrogen peroxide in antimicrobial photodynamic therapy using LED in the blue spectrum against bacteria and biofilm associated with periodontal disease</article-title><source>Photodiagnosis Photodyn. Ther.</source><year>2019</year><volume>26</volume><fpage>306</fpage><lpage>312</lpage><pub-id pub-id-type="doi">10.1016/j.pdpdt.2019.04.015</pub-id><pub-id pub-id-type="pmid">31002887</pub-id>
</element-citation></ref><ref id="B31-pharmaceutics-17-00217"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Leelanarathiwata</surname><given-names>K.</given-names></name>
<name><surname>Katsuta</surname><given-names>Y.</given-names></name>
<name><surname>Katsuragi</surname><given-names>H.</given-names></name>
<name><surname>Watanabe</surname><given-names>F.</given-names></name>
</person-group><article-title>Antibacterial activity of blue high-power light-emitting diode-activated flavin mononucleotide against <italic toggle="yes">Staphylococcus aureus</italic> biofilm on a sandblasted and etched surface</article-title><source>Photodiagnosis Photodyn. Ther.</source><year>2020</year><volume>31</volume><fpage>101855</fpage><pub-id pub-id-type="doi">10.1016/j.pdpdt.2020.101855</pub-id><pub-id pub-id-type="pmid">32512247</pub-id>
</element-citation></ref><ref id="B32-pharmaceutics-17-00217"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Morelato</surname><given-names>L.</given-names></name>
<name><surname>Budimir</surname><given-names>A.</given-names></name>
<name><surname>Smojver</surname><given-names>I.</given-names></name>
<name><surname>Katalini&#x00107;</surname><given-names>I.</given-names></name>
<name><surname>Vuleti&#x00107;</surname><given-names>M.</given-names></name>
<name><surname>Ajanovi&#x00107;</surname><given-names>M.</given-names></name>
<name><surname>Gabri&#x00107;</surname><given-names>D.</given-names></name>
</person-group><article-title>A novel technique for disinfection treatment of contaminated dental implant surface using 0.1% riboflavin and 445 nm diode laser&#x02014;An in vitro study</article-title><source>Bioengineering</source><year>2022</year><volume>9</volume><elocation-id>308</elocation-id><pub-id pub-id-type="doi">10.3390/bioengineering9070308</pub-id><pub-id pub-id-type="pmid">35877359</pub-id>
</element-citation></ref><ref id="B33-pharmaceutics-17-00217"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nielsen</surname><given-names>H.K.</given-names></name>
<name><surname>Garcia</surname><given-names>J.</given-names></name>
<name><surname>V&#x000e6;th</surname><given-names>M.</given-names></name>
<name><surname>Schlafer</surname><given-names>S.</given-names></name>
</person-group><article-title>Comparison of riboflavin and toluidine blue O as photosensitizers for photoactivated disinfection on endodontic and periodontal pathogens in vitro</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><elocation-id>e0140720</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0140720</pub-id><pub-id pub-id-type="pmid">26469348</pub-id>
</element-citation></ref><ref id="B34-pharmaceutics-17-00217"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fiegler-Rudol</surname><given-names>J.</given-names></name>
<name><surname>Zi&#x00119;ba</surname><given-names>N.</given-names></name>
<name><surname>Turski</surname><given-names>R.</given-names></name>
<name><surname>Misio&#x00142;ek</surname><given-names>M.</given-names></name>
<name><surname>Wiench</surname><given-names>R.</given-names></name>
</person-group><article-title>Hypericin-Mediated Photodynamic Therapy for Head and Neck Cancers: A Systematic Review</article-title><source>Biomedicines</source><year>2025</year><volume>13</volume><elocation-id>181</elocation-id><pub-id pub-id-type="doi">10.3390/biomedicines13010181</pub-id><pub-id pub-id-type="pmid">39857765</pub-id>
</element-citation></ref><ref id="B35-pharmaceutics-17-00217"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Etemadi</surname><given-names>H.</given-names></name>
<name><surname>Parker</surname><given-names>S.</given-names></name>
<name><surname>Chiniforush</surname><given-names>N.</given-names></name>
</person-group><article-title>Blue light photodynamic therapy with curcumin and riboflavin in the management of periodontitis: A systematic review</article-title><source>J. Lasers Med. Sci.</source><year>2021</year><volume>12</volume><fpage>e15</fpage><pub-id pub-id-type="doi">10.34172/jlms.2021.15</pub-id><pub-id pub-id-type="pmid">34733738</pub-id>
</element-citation></ref><ref id="B36-pharmaceutics-17-00217"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alqerban</surname><given-names>A.</given-names></name>
</person-group><article-title>Effectiveness of Riboflavin and Rose Bengal Photosensitizer Modified Adhesive Resin for Orthodontic Bonding</article-title><source>Pharmaceuticals</source><year>2021</year><volume>14</volume><elocation-id>48</elocation-id><!--<pub-id pub-id-type="pmcid">PMC7826870</pub-id>--><pub-id pub-id-type="doi">10.3390/ph14010048</pub-id><pub-id pub-id-type="pmid">33435179</pub-id>
</element-citation></ref><ref id="B37-pharmaceutics-17-00217"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kamran</surname><given-names>M.A.</given-names></name>
<name><surname>Qasim</surname><given-names>M.</given-names></name>
<name><surname>Udeabor</surname><given-names>S.E.</given-names></name>
<name><surname>Hameed</surname><given-names>M.S.</given-names></name>
<name><surname>Mannakandath</surname><given-names>M.L.</given-names></name>
<name><surname>Alshahrani</surname><given-names>I.</given-names></name>
</person-group><article-title>Impact of riboflavin mediated photodynamic disinfection around fixed orthodontic system infected with oral bacteria</article-title><source>Photodiagnosis Photodyn. Ther.</source><year>2021</year><volume>34</volume><fpage>102232</fpage><pub-id pub-id-type="doi">10.1016/j.pdpdt.2021.102232</pub-id><pub-id pub-id-type="pmid">33631380</pub-id>
</element-citation></ref><ref id="B38-pharmaceutics-17-00217"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Moradi</surname><given-names>M.</given-names></name>
<name><surname>Fazlyab</surname><given-names>M.</given-names></name>
<name><surname>Pourhajibagher</surname><given-names>M.</given-names></name>
<name><surname>Chiniforush</surname><given-names>N.</given-names></name>
</person-group><article-title>Antimicrobial action of photodynamic therapy on Enterococcus faecalis biofilm using curing light, curcumin and riboflavin</article-title><source>Aust. Endod. J.</source><year>2022</year><volume>48</volume><fpage>274</fpage><lpage>282</lpage><pub-id pub-id-type="doi">10.1111/aej.12565</pub-id><pub-id pub-id-type="pmid">34529329</pub-id>
</element-citation></ref><ref id="B39-pharmaceutics-17-00217"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Najari</surname><given-names>E.</given-names></name>
<name><surname>Zamani</surname><given-names>S.</given-names></name>
<name><surname>Arabi</surname><given-names>M.S.</given-names></name>
<name><surname>Ardebili</surname><given-names>A.</given-names></name>
</person-group><article-title>Antimicrobial photodynamic effect of the photosensitizer riboflavin, alone and in combination with colistin, against pandrug-resistant <italic toggle="yes">Pseudomonas aeruginosa</italic> clinical isolates</article-title><source>J. Infect. Chemother.</source><year>2024</year><volume>30</volume><fpage>892</fpage><lpage>898</lpage><pub-id pub-id-type="doi">10.1016/j.jiac.2024.03.001</pub-id><pub-id pub-id-type="pmid">38432556</pub-id>
</element-citation></ref><ref id="B40-pharmaceutics-17-00217"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alshehri</surname><given-names>A.H.</given-names></name>
</person-group><article-title>Mechanical and antimicrobial effects of riboflavin-mediated photosensitization of in vitro Candida albicans formed on polymethyl methacrylate resin</article-title><source>Photodiagnosis Photodyn. Ther.</source><year>2021</year><volume>36</volume><fpage>102488</fpage><pub-id pub-id-type="doi">10.1016/j.pdpdt.2021.102488</pub-id><pub-id pub-id-type="pmid">34416382</pub-id>
</element-citation></ref><ref id="B41-pharmaceutics-17-00217"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Arboleda</surname><given-names>A.</given-names></name>
<name><surname>Miller</surname><given-names>D.</given-names></name>
<name><surname>Cabot</surname><given-names>F.</given-names></name>
<name><surname>Taneja</surname><given-names>M.</given-names></name>
<name><surname>Aguilar</surname><given-names>M.C.</given-names></name>
<name><surname>Alawa</surname><given-names>K.</given-names></name>
<name><surname>Amescua</surname><given-names>G.</given-names></name>
<name><surname>Yoo</surname><given-names>S.H.</given-names></name>
<name><surname>Parel</surname><given-names>J.-M.</given-names></name>
</person-group><article-title>Assessment of rose bengal versus riboflavin photodynamic therapy for inhibition of fungal keratitis isolates</article-title><source>Am. J. Ophthalmol.</source><year>2014</year><volume>158</volume><fpage>64</fpage><lpage>70.e2</lpage><pub-id pub-id-type="doi">10.1016/j.ajo.2014.04.007</pub-id><pub-id pub-id-type="pmid">24792103</pub-id>
</element-citation></ref><ref id="B42-pharmaceutics-17-00217"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kashiwabuchi</surname><given-names>R.T.</given-names></name>
<name><surname>Carvalho</surname><given-names>F.R.</given-names></name>
<name><surname>Khan</surname><given-names>Y.A.</given-names></name>
<name><surname>Hirai</surname><given-names>F.</given-names></name>
<name><surname>Campos</surname><given-names>M.S.</given-names></name>
<name><surname>McDonnell</surname><given-names>P.J.</given-names></name>
</person-group><article-title>Assessment of fungal viability after long-wave ultraviolet light irradiation combined with riboflavin administration</article-title><source>Graefes Arch. Clin. Exp. Ophthalmol.</source><year>2013</year><volume>251</volume><fpage>521</fpage><lpage>527</lpage><pub-id pub-id-type="doi">10.1007/s00417-012-2209-z</pub-id><pub-id pub-id-type="pmid">23180236</pub-id>
</element-citation></ref><ref id="B43-pharmaceutics-17-00217"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sholapurkar</surname><given-names>A.</given-names></name>
<name><surname>Sharma</surname><given-names>D.</given-names></name>
<name><surname>Glass</surname><given-names>B.</given-names></name>
<name><surname>Miller</surname><given-names>C.</given-names></name>
<name><surname>Nimmo</surname><given-names>A.</given-names></name>
<name><surname>Jennings</surname><given-names>E.</given-names></name>
</person-group><article-title>Professionally Delivered Local Antimicrobials in the Treatment of Patients with Periodontitis&#x02014;A Narrative Review</article-title><source>Dent. J.</source><year>2020</year><volume>9</volume><elocation-id>2</elocation-id><!--<pub-id pub-id-type="pmcid">PMC7822216</pub-id>--><pub-id pub-id-type="doi">10.3390/dj9010002</pub-id><pub-id pub-id-type="pmid">33375176</pub-id>
</element-citation></ref><ref id="B44-pharmaceutics-17-00217"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>B&#x000fc;chtner</surname><given-names>A.</given-names></name>
<name><surname>Meyer</surname><given-names>U.</given-names></name>
<name><surname>Kruse-L&#x000f6;sler</surname><given-names>B.</given-names></name>
<name><surname>Joos</surname><given-names>U.</given-names></name>
<name><surname>Kleinheinz</surname><given-names>J.</given-names></name>
</person-group><article-title>Sustained release of doxycycline for the treatment of peri-implantitis: Randomised controlled trial</article-title><source>Br. J. Oral Maxillofac. Surg.</source><year>2004</year><volume>42</volume><fpage>439</fpage><lpage>444</lpage><pub-id pub-id-type="doi">10.1016/j.bjoms.2004.06.005</pub-id><pub-id pub-id-type="pmid">15336770</pub-id>
</element-citation></ref><ref id="B45-pharmaceutics-17-00217"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Micu</surname><given-names>I.C.</given-names></name>
<name><surname>Muntean</surname><given-names>A.</given-names></name>
<name><surname>Roman</surname><given-names>A.</given-names></name>
<name><surname>Stratul</surname><given-names>&#x00218;.I.</given-names></name>
<name><surname>Pall</surname><given-names>E.</given-names></name>
<name><surname>Ciurea</surname><given-names>A.</given-names></name>
<name><surname>Soanc&#x00103;</surname><given-names>A.</given-names></name>
<name><surname>Negucioiu</surname><given-names>M.</given-names></name>
<name><surname>Barbu Tudoran</surname><given-names>L.</given-names></name>
<name><surname>Delean</surname><given-names>A.G.</given-names></name>
</person-group><article-title>A Local Desiccant Antimicrobial Agent as an Alternative to Adjunctive Antibiotics in the Treatment of Periodontitis: A Narrative Review</article-title><source>Antibiotics</source><year>2023</year><volume>12</volume><elocation-id>456</elocation-id><!--<pub-id pub-id-type="pmcid">PMC10044681</pub-id>--><pub-id pub-id-type="doi">10.3390/antibiotics12030456</pub-id><pub-id pub-id-type="pmid">36978324</pub-id>
</element-citation></ref><ref id="B46-pharmaceutics-17-00217"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tomasi</surname><given-names>C.</given-names></name>
<name><surname>Koutouzis</surname><given-names>T.</given-names></name>
<name><surname>Wennstr&#x000f6;m</surname><given-names>J.</given-names></name>
</person-group><article-title>Locally Delivered Doxycycline as an Adjunct to Mechanical Debridement at Retreatment of Periodontal Pockets</article-title><source>J. Periodontol.</source><year>2008</year><volume>79</volume><fpage>431</fpage><lpage>439</lpage><pub-id pub-id-type="doi">10.1902/jop.2008.070383</pub-id><pub-id pub-id-type="pmid">18315425</pub-id>
</element-citation></ref><ref id="B47-pharmaceutics-17-00217"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Toledano</surname><given-names>M.</given-names></name>
<name><surname>Osorio</surname><given-names>M.T.</given-names></name>
<name><surname>Vallecillo-Rivas</surname><given-names>M.</given-names></name>
<name><surname>Toledano-Osorio</surname><given-names>M.</given-names></name>
<name><surname>Rodr&#x000ed;guez-Archilla</surname><given-names>A.</given-names></name>
<name><surname>Toledano</surname><given-names>R.</given-names></name>
<name><surname>Osorio</surname><given-names>R.</given-names></name>
</person-group><article-title>Efficacy of local antibiotic therapy in the treatment of peri-implantitis: A systematic review and meta-analysis</article-title><source>J. Dent.</source><year>2021</year><volume>113</volume><fpage>103790</fpage><pub-id pub-id-type="doi">10.1016/j.jdent.2021.103790</pub-id><pub-id pub-id-type="pmid">34455016</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="pharmaceutics-17-00217-f001"><label>Figure 1</label><caption><p>A Schematic representation of clinical and chemical aspects of riboflavin-mediated PDT [<xref rid="B4-pharmaceutics-17-00217" ref-type="bibr">4</xref>].</p></caption><graphic xlink:href="pharmaceutics-17-00217-g001" position="float"/></fig><fig position="float" id="pharmaceutics-17-00217-f002"><label>Figure 2</label><caption><p>Prisma 2020 flow diagram.</p></caption><graphic xlink:href="pharmaceutics-17-00217-g002" position="float"/></fig><table-wrap position="float" id="pharmaceutics-17-00217-t001"><object-id pub-id-type="pii">pharmaceutics-17-00217-t001_Table 1</object-id><label>Table 1</label><caption><p>Search syntax used in the study.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Source</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Search Term</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Filters</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Number of Results</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Medline via<break/>PubMed</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(riboflavin OR &#x0201c;vitamin B2&#x0201d;) AND (&#x0201c;photodynamic therapy&#x0201d; OR photochemotherapy OR phototherapy OR PDT OR &#x0201c;light-activated disinfection&#x0201d; OR photosensitizer OR photosensitizing OR &#x0201c;light therapy&#x0201d;)<break/>AND (periodontal OR periodontics OR periodontology OR periodontitis OR periodont* OR gingivitis OR &#x0201c;gum disease&#x0201d; OR &#x0201c;gum infection&#x0201d;)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2015&#x02013;2025</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Web of<break/>Science<break/>Scopus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(TITLE-ABS-KEY (riboflavin OR &#x0201c;vitamin B2&#x0201d;)) AND (TITLE-ABS-KEY(&#x0201c;photodynamic therapy&#x0201d; OR photochemotherapy OR phototherapy OR PDT OR &#x0201c;light-activated disinfection&#x0201d; OR photosensitizer OR photosensitizing OR &#x0201c;light therapy&#x0201d;)) AND (TITLE-ABS-KEY (periodontal OR periodontics OR periodontology OR periodontitis OR periodont* OR gingivitis OR &#x0201c;gum disease&#x0201d; OR &#x0201c;gum infection&#x0201d;))</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2015&#x02013;2025</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Embase</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">((&#x02018;riboflavin&#x02019;: ti, ab, kw OR &#x02018;vitamin B2&#x02019;: ti, ab, kw)) AND ((&#x02018;photodynamic therapy&#x02019;: ti, ab, kw OR photochemotherapy: ti, ab, kw OR phototherapy: ti, ab, kw OR pdt: ti, ab, kw OR &#x02018;light-activated disinfection&#x02019;: ti, ab, kw OR photosensitizer: ti, ab, kw OR photosensitizing: ti, ab, kw OR &#x02018;light therapy&#x02019;: ti, ab, kw)) AND ((periodontal: ti, ab, kw OR periodontics: ti, ab, kw OR periodontology: ti, ab, kw OR periodontitis: ti, ab, kw OR periodont*: ti, ab, kw OR gingivitis: ti, ab, kw OR &#x02018;gum disease&#x02019;: ti, ab, kw OR &#x02018;gum infection&#x02019;: ti, ab, kw))</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2015&#x02013;2025</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cochrane database</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(MH &#x0201c;Riboflavin&#x0201d; OR &#x0201c;Riboflavin&#x0201d; OR &#x0201c;Vitamin B2&#x0201d;) AND (MH &#x0201c;Photodynamic Therapy&#x0201d; OR &#x0201c;Photodynamic Therapy&#x0201d; OR &#x0201c;PDT&#x0201d; OR &#x0201c;Photochemotherapy&#x0201d; OR &#x0201c;Antimicrobial Photodynamic Therapy&#x0201d; OR &#x0201c;Light-Activated Disinfection&#x0201d; OR &#x0201c;Photosensitizer&#x0201d; OR &#x0201c;Photosensitizing&#x0201d; OR &#x0201c;Light Therapy&#x0201d;) AND (MH &#x0201c;Dentistry&#x0201d; OR MH &#x0201c;Oral Health&#x0201d; OR &#x0201c;Periodontal&#x0201d; OR &#x0201c;Periodontics&#x0201d; OR &#x0201c;Periodontology&#x0201d; OR &#x0201c;Periodontitis&#x0201d; OR &#x0201c;Periodont*&#x0201d; OR &#x0201c;Gingivitis&#x0201d; OR &#x0201c;Gum Disease&#x0201d; OR &#x0201c;Gum Infection&#x0201d;)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2015&#x02013;2025</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td></tr></tbody></table></table-wrap><table-wrap position="float" id="pharmaceutics-17-00217-t003"><object-id pub-id-type="pii">pharmaceutics-17-00217-t003_Table 3</object-id><label>Table 3</label><caption><p>Summary of the studies.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Author and Year</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Country</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Study Design</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Programs Used (Version, Specifications, Model, Brand, Company, City, State, Country)</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Afrasiabi et al. 2023 [<xref rid="B25-pharmaceutics-17-00217" ref-type="bibr">25</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Iran</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">in vitro study</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Blue diode laser (0.4&#x02013;1.0 W/cm<sup>2</sup>), Curcumin and Riboflavin, Chlorhexidine, Laser Research Center of Dentistry, Tehran University of Medical Sciences, Tehran, Iran</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">B&#x000e4;renfaller et al., 2016 [<xref rid="B26-pharmaceutics-17-00217" ref-type="bibr">26</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Switzerland</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">in vitro study</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Photoactivated disinfection using LED (Blue and Red), Riboflavin, University of Bern, Freiburgstrasse, Bern, Switzerland</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Comeau et al., 2022 [<xref rid="B27-pharmaceutics-17-00217" ref-type="bibr">27</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Canada</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">in vitro study</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Blue LED (1.3 J/cm<sup>2</sup>), Riboflavin-loaded dental resin, University of British Columbia, Vancouver, Canada</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Etemadi et al., 2023 [<xref rid="B28-pharmaceutics-17-00217" ref-type="bibr">28</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Iran</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">in vitro study</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LED irradiation (390&#x02013;480 nm), Curcumin and Riboflavin, Chlorhexidine 0.12%, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Kang et al., 2019 [<xref rid="B29-pharmaceutics-17-00217" ref-type="bibr">29</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">South Korea</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">in vitro study</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">405 nm blue light (25.3 J), Curcumin, Protoporphyrin-IX, Resazurin, Riboflavin, Yonsei University College of Dentistry, Seoul, South Korea</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Kunz et al., 2019 [<xref rid="B30-pharmaceutics-17-00217" ref-type="bibr">30</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Switzerland</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">in vitro study</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Blue LED (30 s, 60 s), Riboflavin, Hydrogen Peroxide, University of Bern, Switzerland</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Leelanarathiwata et al., 2020 [<xref rid="B31-pharmaceutics-17-00217" ref-type="bibr">31</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Thailand</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">in vitro study</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Blue high-power LED, Flavin Mononucleotide, Mahidol University, Bangkok, Thailand</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Morelato et al., 2022 [<xref rid="B32-pharmaceutics-17-00217" ref-type="bibr">32</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Croatia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">in vitro study</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">445 nm diode laser, Riboflavin, University of Rijeka, Croatia</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nielsen et al., 2015 [<xref rid="B33-pharmaceutics-17-00217" ref-type="bibr">33</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Denmark</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">in vitro study</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Blue LED, Riboflavin and Toluidine Blue O, Aarhus University, Denmark</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Qamar et al., 2023 [<xref rid="B24-pharmaceutics-17-00217" ref-type="bibr">24</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Saudi Arabia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Randomized controlled trial</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Riboflavin-loaded Poly-L-glycolic acid nanoparticles, Aloe Vera gel, Riyadh Elm University, Riyadh, Saudi Arabia (Marked in Blue)</td></tr></tbody></table></table-wrap><table-wrap position="float" id="pharmaceutics-17-00217-t004"><object-id pub-id-type="pii">pharmaceutics-17-00217-t004_Table 4</object-id><label>Table 4</label><caption><p>Main outcomes and study groups.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Author and Year</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Study Groups</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Main Outcomes</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Afrasiabi et al., 2023 [<xref rid="B25-pharmaceutics-17-00217" ref-type="bibr">25</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Negative Control: No treatment.<break/>Positive Control: Bacterial suspension exposed to CHX at 25 &#x000b0;C for 1 min.<break/>Curcumin Only: Bacterial suspension exposed to curcumin (40 &#x000b5;M) in the dark at 25 &#x000b0;C for 5 min.<break/>Riboflavin Only: Bacterial suspension exposed to riboflavin (100 &#x000b5;M) in the dark at 25 &#x000b0;C for 5 min.<break/>aPDT with Curcumin + Blue Diode Laser<break/>aPDT with Riboflavin + Blue Diode Laser</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Riboflavin-mediated PDT demonstrates significant bactericidal effects against periodontal pathogens like <italic toggle="yes">Streptococcus mutans</italic>, particularly when combined with a blue diode laser at optimized power densities. The study found that riboflavin, activated by 445 nm blue light, induces oxidative stress, leading to microbial decontamination. The bactericidal efficacy improves with increased laser power density, with maximum effect observed at 1.0 W/cm<sup>2</sup>. Compared to conventional antimicrobial agents such as chlorhexidine, riboflavin-mediated PDT offers a non-invasive alternative, reducing bacterial colonies without systemic side effects, thus enhancing its potential as a sustainable periodontal therapy.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">B&#x000e4;renfaller et al., 2016 [<xref rid="B26-pharmaceutics-17-00217" ref-type="bibr">26</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Negative Control: No treatment.<break/>Light Control: light only.<break/>Photosensitizer Control: Without light.<break/>PAD30 (Blue LED): Photoactivated disinfection with blue LED for 30 s with riboflavin as photosensitizer.<break/>PAD60 (Blue LED): Photoactivated disinfection with blue LED for 60 s with riboflavin as photosensitizer.<break/>PADred: Photoactivated disinfection with red LED for 60 s with toluidine blue as photosensitizer.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Riboflavin-mediated PDT, often combined with blue spectrum LED, demonstrates notable antimicrobial effects against periodontopathogenic species. Studies highlight its efficacy in reducing planktonic bacterial counts, including pathogens such as <italic toggle="yes">Porphyromonas gingivalis</italic> and <italic toggle="yes">Aggregatibacter actinomycetemcomitans</italic>. However, the bactericidal impact is time and dose-dependent, with increased exposure enhancing outcomes. Riboflavin-mediated PDT shows diminished efficacy in complex multi-species biofilms and in the presence of serum, underlining the importance of mechanical biofilm removal as an adjunct. Despite its promising potential, riboflavin-mediated PDT&#x02019;s effectiveness is generally inferior to red-spectrum light systems using toluidine blue. Its clinical relevance lies in supplementing traditional periodontal therapies while minimizing antibiotic resistance risks</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Comeau et al., 2022 [<xref rid="B27-pharmaceutics-17-00217" ref-type="bibr">27</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Control Groups:<break/>Resin blend without riboflavin (0% B<sub>2</sub>).<break/>Bacterial biofilm-only group (<italic toggle="yes">Streptococcus mutans</italic>) without resin disks.<break/>Experimental Resin Groups:<break/>Riboflavin-loaded resins with concentrations: 0.1%, 1.0%, and 1.5% B<sub>2</sub>.<break/>Light Treatment Sub-Groups:<break/>Dark: No light exposure.<break/>Light: Exposure to blue LED light (440&#x02013;460 nm) for 60 s at a fluence of 1.3 J/cm<sup>2</sup>.<break/>Aging Conditions:<break/>Immediate: Resin specimens sterilized and tested immediately after fabrication.<break/>Aged: Resin specimens stored in 37 &#x000b0;C ultrapure water for 28 days before testing.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Riboflavin-mediated photodynamic therapy (PDT) in periodontology demonstrates significant antimicrobial and restorative potential. As a photosensitizer, riboflavin is activated by blue light to produce ROS that effectively reduce bacterial viability, particularly against pathogens like <italic toggle="yes">Porphyromonas gingivalis</italic>, <italic toggle="yes">Aggregatibacter actinomycetemcomitans</italic>, and <italic toggle="yes">Streptococcus mutans</italic>. Its efficacy is enhanced with optimized light parameters, such as higher fluence rates and appropriate exposure times, though it is less effective against complex biofilms and in the presence of serum. Studies show that riboflavin-mediated PDT can decrease biofilm formation on dental materials and integrate into resin-based restorations, providing mechanical stability and antimicrobial activity without compromising material properties. Further optimization of concentration, light parameters, and biofilm models is necessary to maximize its clinical applicability.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Etemadi et al., 2023 [<xref rid="B28-pharmaceutics-17-00217" ref-type="bibr">28</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Negative Control: No treatment<break/>Positive Control: 0.12% chlorhexidine (5 s)<break/>Curcumin Group: 5 mg/mL curcumin in the dark for 5 min.<break/>Riboflavin Group: 0.5% riboflavin in the dark for 5 min.<break/>LED Group: Exposed to blue light (390&#x02013;480 nm) for 60 s.<break/>Curcumin-mediated PDT: 5 mg/mL + LED.<break/>Riboflavin-mediated PDT: 0.5% + LED.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Riboflavin-mediated PDT in periodontology and peri-implantology exhibits promising antimicrobial effects, especially against <italic toggle="yes">Aggregatibacter actinomycetemcomitans</italic>. When activated by blue light or LEDs in the 390&#x02013;480 nm range, riboflavin generates ROS that disrupt bacterial membranes, reducing biofilm viability on teeth and implant surfaces. Riboflavin mediated PDT effectively lowers bacterial CFU/mL in vitro, with better results under optimized conditions such as higher light intensity and adequate exposure time. Although generally less effective than curcumin-mediated PDT or chlorhexidine, riboflavin-mediated PDT offers a biocompatible, non-invasive alternative that avoids systemic side effects and minimizes antibiotic resistance risks. While its ability to kill biofilms is clear, clinical use may be limited by complex biofilm structures and low oxygen levels in deep periodontal pockets.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Kang et al., 2019 [<xref rid="B29-pharmaceutics-17-00217" ref-type="bibr">29</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 photosensitizers tested:<break/>Curcumin: 100 &#x003bc;g/mL, 10 &#x003bc;g/mL, 1 &#x003bc;g/mL, and 0.1 &#x003bc;g/mL.<break/>Protoporphyrin IX: Same concentrations as curcumin.<break/>Resazurin: Same concentrations as curcumin.<break/>Riboflavin: Same concentrations as curcumin.<break/>Light Exposure: 405 nm violet-blue LED irradiation (25.3 J).<break/>Dark Condition: No light exposure (PS only).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Riboflavin-mediated PDT demonstrated antimicrobial effects against <italic toggle="yes">Veillonella parvula</italic> but showed limited or no activity against <italic toggle="yes">Lactobacillus gasseri</italic> at lower concentrations. Its efficacy varied across bacterial strains, emphasizing its potential for selective bacterial inhibition in periodontal therapy while highlighting the need for optimization in biofilm models and clinical applications.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Kunz et al., 2019 [<xref rid="B30-pharmaceutics-17-00217" ref-type="bibr">30</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Control Group: 0.9% NaCl.<break/>Riboflavin (0.1%) + 30 s of blue LED light.<break/>Riboflavin (0.1%) + 60 s of blue LED light.<break/>0.25% H<sub>2</sub>O<sub>2</sub> + Riboflavin + 30 s of blue LED light.<break/>0.25% H<sub>2</sub>O<sub>2</sub> + Riboflavin + 60 s of blue LED light.<break/>3% H<sub>2</sub>O<sub>2</sub> + Riboflavin + 30 s of blue LED light.<break/>3% H<sub>2</sub>O<sub>2</sub> + Riboflavin + 60 s of blue LED light.<break/>Mechanical biofilm removal only.<break/>Mechanical biofilm removal + 0.25% H<sub>2</sub>O<sub>2</sub> + Riboflavin + 60 s of blue LED light.<break/>Mechanical biofilm removal + 3% H<sub>2</sub>O<sub>2</sub> + Riboflavin + 60 s of blue LED light.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">It demonstrates that while aPDT alone has limited activity against biofilms, its efficacy significantly increases when preceded by H<sub>2</sub>O<sub>2</sub> pretreatment, particularly at a 3% concentration. This combined approach effectively eliminates planktonic bacteria and multi-species biofilms, with no detectable bacteria remaining when coupled with mechanical biofilm removal. This method could provide a potent alternative to traditional antimicrobial periodontal therapies, reducing the reliance on antibiotics and their associated resistance issues.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Leelanarathiwata et al., 2020 [<xref rid="B31-pharmaceutics-17-00217" ref-type="bibr">31</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Control Group: No treatment.<break/>Light Irradiation Only Groups: Red diode laser (for 60 s). Blue high-power LED (for 10 s).<break/>Red Laser + Methylene Blue<break/>Blue LED + FMN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Riboflavin-mediated PDT, employing flavin mononucleotide activated by blue high-power LED light, demonstrates significant antibacterial efficacy against <italic toggle="yes">Staphylococcus aureus</italic> biofilms, a key contributor to peri-implantitis. This novel approach yields bacterial reductions comparable to established methylene blue&#x02013;based PDT with red laser activation, achieving over 93% bacterial reduction. Riboflavin&#x02019;s natural presence and safer profile, combined with shorter treatment durations and effective biofilm penetration, position it as a promising alternative or adjunctive treatment to conventional scaling, root planing, and antibiotics, particularly amidst rising antibiotic resistance. While both PDT systems effectively reduce biofilm mass and bacterial viability, riboflavin&#x02019;s activation by blue light offers aesthetic and operational advantages, though further optimization and studies are needed for deeper tissue applications and enhanced biofilm eradication.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Morelato et al., 2022 [<xref rid="B32-pharmaceutics-17-00217" ref-type="bibr">32</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Negative Control: Untreated implants.<break/>Positive Control: Implants treated with 0.2% CHX s for 60 s using brushing movements.<break/>PDT Groups:<break/>PDT1 (660 nm diode laser): Methylene blue (0.1%) as a photosensitizer, activated with a 660 nm diode laser for 60 s.<break/>PDT2 (445 nm diode laser): Riboflavin (0.1%) as a photosensitizer, activated with a 445 nm diode laser for 60 s.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Riboflavin-mediated PDT, specifically utilizing a 445 nm diode laser combined with 0.1% riboflavin as a photosensitizer, demonstrates significant efficacy in reducing biofilms of <italic toggle="yes">Staphylococcus aureus</italic> and <italic toggle="yes">Candida albicans</italic> on dental implant surfaces. This method shows comparable outcomes to conventional 660 nm diode laser PDT with methylene blue and 0.2% CHX treatments, without significant differences in microbial reduction among these methods. Advantages include minimal aesthetic disruption due to riboflavin&#x02019;s light-yellow colour, which contrasts with the staining caused by methylene blue. The technique proves to be a promising adjunct to mechanical debridement for peri-implantitis, particularly in aesthetic zones, although it does not completely eradicate all microorganisms or organic material.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nielsen et al., 2015 [<xref rid="B33-pharmaceutics-17-00217" ref-type="bibr">33</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Negative Control Group (P&#x02212;L&#x02212;): Microbial suspension treated with sterile saline without light or photosensitizer.<break/>Light Alone Group (P&#x02212;L+): Microbial suspension irradiated with light (red or blue LED) without photosensitizer.<break/>Photosensitizer Alone Group (P+L&#x02212;): Microbial suspension treated with photosensitizer without light.<break/>Photoactivated Disinfection (PAD) Groups (P+L+):<break/>Riboflavin + Blue Light:<break/>Treated with riboflavin and irradiated with 460 nm blue LED.<break/>Toluidine Blue O + Red Light:<break/>Treated with toluidine blue O and irradiated with 630 nm red LED.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Riboflavin-mediated PDT with blue light showed limited antimicrobial effects compared to TBO with red light for periodontal and endodontic pathogens. Although riboflavin effectively reduced <italic toggle="yes">Porphyromonas gingivalis</italic> and <italic toggle="yes">Prevotella intermedia</italic>, similar reductions occurred with blue light alone, indicating activation of bacterial endogenous chromophores. For other pathogens, riboflavin only caused minor to moderate bacterial reductions, and longer irradiation times did not enhance efficacy within clinical limits. In contrast, TBO-mediated PAD completely eradicated all tested pathogens even with short irradiation, demonstrating superior antimicrobial efficacy. Thus, riboflavin is unsuitable as a photosensitizer for periodontal or endodontic infections, while TBO shows significant promise.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Qamar et al., 2023 [<xref rid="B24-pharmaceutics-17-00217" ref-type="bibr">24</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Group 1: PGA/RF/AV + MD<break/>Group 2: PDT + MD<break/>Group 3: MD Alone</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">While PDT alone significantly reduced BoP and microbial loads of Tf, the application of PGA/RF/AV demonstrated better outcomes. This compound significantly improved PD, PI, and MBL, with enhanced reductions in microbial counts of both <italic toggle="yes">Porphyromonas gingivalis</italic> and Tf. These findings highlight the potential of the PGA/RF/AV complex as a more effective treatment modality than PDT alone, leveraging the bactericidal and anti-inflammatory properties of riboflavin and aloe vera to achieve improved clinical and microbiological outcomes.</td></tr></tbody></table><table-wrap-foot><fn><p>aPDT&#x02014;Antimicrobial Photodynamic Therapy; AV&#x02014;Aloe Vera; B<sub>2</sub>&#x02014;Vitamin B<sub>2</sub> (Riboflavin); CFU&#x02014;Colony-Forming Unit(s); CHX&#x02014;Chlorhexidine; FMN&#x02014;Flavin Mononucleotide; H<sub>2</sub>O<sub>2</sub>&#x02014;Hydrogen Peroxide; J&#x02014;Joule; LED&#x02014;Light-Emitting Diode; MD&#x02014;Mechanical Debridement; MBL&#x02014;Marginal Bone Level; PD&#x02014;Probing Depth; PGA&#x02014;Poly-L-Glycolic Acid; PI&#x02014;Plaque Index; PDT&#x02014;Photodynamic Therapy; P&#x02212;L&#x02212;&#x02014;No Photosensitizer and No Light; P+L&#x02212;&#x02014;Photosensitizer Only; P&#x02212;L+&#x02014;Light Only; P+L+&#x02014;Photoactivated Disinfection; PS&#x02014;Photosensitizer; RF&#x02014;Riboflavin; TBO&#x02014;Toluidine Blue O; Tf&#x02014;<italic toggle="yes">Tannerella forsythia</italic>; BoP&#x02014;Bleeding on Probing; PGA/RF/AV&#x02014;Riboflavin-Loaded Poly-L-Glycolic Acid Nanoparticles in Aloe Vera Gel; PI&#x02014;Plaque Index; MBL&#x02014;Marginal Bone Level.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="pharmaceutics-17-00217-t005"><object-id pub-id-type="pii">pharmaceutics-17-00217-t005_Table 5</object-id><label>Table 5</label><caption><p>Summary of light source parameters from each study.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Light Source</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Author/Year</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Operating Mode</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Wavelength<break/>(nm)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Energy Density (Fluence)<break/>(J/cm<sup>2</sup>)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Power Output<break/>(mW)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Irradiation Time<break/>(s)</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Blue diode laser (Pioon, China)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Afrasiabi et al., 2023 [<xref rid="B25-pharmaceutics-17-00217" ref-type="bibr">25</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Continuous</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">445 nm</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12, 18, 24, and 30 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30 s</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FotoSan460; CMS Dental ApS, Copenhagen, Denmark</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">B&#x000e4;renfaller et al., 2016 [<xref rid="B26-pharmaceutics-17-00217" ref-type="bibr">26</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Continuous</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">460 &#x000b1; 10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">120</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30, 60</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BioLight (Department of Physics and Astronomy at the University of British Columbia, Vancouver, BC, Canada)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Comeau et al., 2022 [<xref rid="B27-pharmaceutics-17-00217" ref-type="bibr">27</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Continuous</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">440&#x02013;460</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">830</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">60</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LED (DY400-4, Denjoy, China)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Etemadi et al., 2023 [<xref rid="B28-pharmaceutics-17-00217" ref-type="bibr">28</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Continuous</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">390&#x02013;480</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">300&#x02013;420</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1000 &#x000b1; 100</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">QLF-D (s<break/>digital, Inspektor Research Systems, Amsterdam,<break/>The Netherlands)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Kang et al., 2019 [<xref rid="B29-pharmaceutics-17-00217" ref-type="bibr">29</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Continuous</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">405</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">84.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FotoSan460; CMS Dental ApS, Copenhagen, Denmark).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Kunz et al., 2019 [<xref rid="B30-pharmaceutics-17-00217" ref-type="bibr">30</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Continuous</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">460 &#x000b1; 10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30, 60</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FotoSan<sup>&#x000ae;</sup> BLUE LAD; (CMS Dental, Denmark)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Leelanarathiwata et al., 2020 [<xref rid="B31-pharmaceutics-17-00217" ref-type="bibr">31</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Continuous</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">450&#x02013;470</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">37&#x02013;40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29.1&#x02212;31.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Diode laser (SiroLaser Blue, Dentsply Sirona, Bensheim, Germany)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Morelato et al., 2022 [<xref rid="B32-pharmaceutics-17-00217" ref-type="bibr">32</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pulsed mode<break/>(100 Hz)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">445</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.24</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">60</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FotoSan 630 LAD pen<break/>FlashMax P3 460<break/>(CMS Dental, Denmark)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nielsen et al., 2015 [<xref rid="B33-pharmaceutics-17-00217" ref-type="bibr">33</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Continuous</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">630<break/>460</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">37.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">60</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Diode laser system (Periowave&#x02122; Vancouver, BC, Canada)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Qamar et al., 2023 [<xref rid="B24-pharmaceutics-17-00217" ref-type="bibr">24</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Continuous</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">670</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">280</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">60</td></tr></tbody></table><table-wrap-foot><fn><p>LED&#x02014;Light-Emitting Diode; QLF-D&#x02014;Quantitative Light-Induced Fluorescence Device.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="pharmaceutics-17-00217-t006"><object-id pub-id-type="pii">pharmaceutics-17-00217-t006_Table 6</object-id><label>Table 6</label><caption><p>Summary of photosynthesizer concentrations and incubation times.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Author and Year</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Concentration/s of Riboflavin Used</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Afrasiabi et al., 2023 [<xref rid="B25-pharmaceutics-17-00217" ref-type="bibr">25</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">100 &#x000b5;M</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">B&#x000e4;renfaller et al., 2016 [<xref rid="B26-pharmaceutics-17-00217" ref-type="bibr">26</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.1%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Comeau et al., 2022 [<xref rid="B27-pharmaceutics-17-00217" ref-type="bibr">27</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.1&#x02013;1.5%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Etemadi et al., 2023 [<xref rid="B28-pharmaceutics-17-00217" ref-type="bibr">28</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.5%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Kang et al., 2019 [<xref rid="B29-pharmaceutics-17-00217" ref-type="bibr">29</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">10 &#x000b5;g/mL</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Kunz et al., 2019 [<xref rid="B30-pharmaceutics-17-00217" ref-type="bibr">30</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.1%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Leelanarathiwata et al., 2020 [<xref rid="B31-pharmaceutics-17-00217" ref-type="bibr">31</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.18 FMN</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Morelato et al., 2022 [<xref rid="B32-pharmaceutics-17-00217" ref-type="bibr">32</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.1%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Nielsen et al., 2015 [<xref rid="B33-pharmaceutics-17-00217" ref-type="bibr">33</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">133 &#x003bc;mol/L inplanktonic microbial suspension</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Qamar et al., 2023 [<xref rid="B24-pharmaceutics-17-00217" ref-type="bibr">24</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.1%</td></tr></tbody></table><table-wrap-foot><fn><p>FMN-riboflavin-5&#x02032;-phosphate.</p></fn></table-wrap-foot></table-wrap></floats-group></article>